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pathological a-syn inclusions are refractory to clearance. Importantly, while proteasome function appears
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may play a role in the increased cell death observed in aggregate-bearing cells. Our results indicate that, after
accumulation LB-like of a-syn aggregates, activation of Pdps may not effectively clear pathology or enhance
cell survival. However, treatments that could prevent the inhibitory effect of a-syn aggregates on autophagy
may be beneficial. We believe this work improves our understanding of the role of a-syn aggregates in
synucleinopathies, and it may contribute to the efforts to develop potential therapies for these devastating
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ABSTRACT 
 
THE INTERPLAY BETWEEN LEWY BODY-LIKE ALPHA-SYNUCLEIN 
AGGREGATES AND PROTEIN DEGRADATION PATHWAYS IN A CELL-
BASED MODEL OF PARKINSON’S DISEASE  
 
Selcuk Aski Tanik 
 
Virginia M.-Y. Lee 
 
Cytoplasmic alpha-synuclein (α-syn) aggregates, including Lewy bodies (LBs), are pathological 
hallmarks of a number of neurodegenerative diseases, most notably Parkinson‟s disease (PD). 
Activation of intracellular protein degradation pathways (Pdps) to eliminate these aggregates has 
been proposed as a therapeutic approach for PD and other synucleinopathies, but the interplay 
between LB-like α-syn aggregates and Pdps is not completely understood. Here, we investigate 
this interplay by utilizing a recently developed cellular model in which intracellular LB-like α-syn 
inclusions accumulate after delivery of pre-formed α-syn fibrils (Pffs) into α-syn-expressing 
HEK293 cells or cultured primary neurons. This thesis describes the interplay between LB-like 
aggregates and Pdps, as well as the examination and optimization of the cellular model for this 
study. We demonstrate that the efficiency of the model can be greatly improved by use of mutant 
α-syn expressing cells and truncated Pffs. We also show that only a minute amount of Pffs that 
gain access to cells, and the LB-like aggregates are primarily composed of endogenous α-syn, 
thereby rendering levels of insoluble endogenous α-syn an excellent read-out for our study. 
Utilizing the optimized model, we show that α-syn inclusions cannot be effectively degraded by 
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Pdps, even though they colocalize with essential components of these pathways. Furthermore, 
once formed, α-syn aggregates persist even after reduction of soluble α-syn levels, suggesting that 
pathologic α-syn inclusions are refractory to clearance. Importantly, while proteasome function 
appears unaltered, we find that α-syn aggregates impair macroautophagy by reducing 
autophagosome clearance, which may play a role in the increased cell death observed in 
aggregate-bearing cells. Our results indicate that, after accumulation LB-like of α-syn aggregates, 
activation of Pdps may not effectively clear pathology or enhance cell survival. However, 
treatments that could prevent the inhibitory effect of α-syn aggregates on autophagy may be 
beneficial. We believe this work improves our understanding of the role of α-syn aggregates in 
synucleinopathies, and it may contribute to the efforts to develop potential therapies for these 
devastating diseases. 
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Chapter 1: General Introduction 
 
1.1 Parkinson’s disease and other synucleinopathies 
 Parkinson‟s disease (PD) is the most common neurodegenerative movement 
disorder and it is the second most common neurodegenerative disorder after Alzheimer‟s 
disease (AD) (de Lau & Breteler, 2006). It is estimated that over 10 million people are 
impaired by PD, and this number is expected to significantly increase with aging 
population (de Lau & Breteler, 2006). Motor symptoms of PD include resting tremor, 
muscle rigidity and slowness of movement (bradykinesia). These most prominent 
symptoms of PD are caused by loss of dopaminergic neurons in substantia nigra pars 
compacta (SNc) and resulting brain dopamine insufficiency (Figure 1-1). Currently, PD 
patients are routinely treated by medications that exert their effects by increasing 
dopamine levels in brain. However, this approach only alleviates the motor symptoms, 
and progressive neurodegeneration typically decreases responsiveness to such therapies 
and eventually the symptoms worsen, in some extreme cases to the extent of complete 
loss of movement (akinesia). Dopamine replacement therapies are also ineffective against 
dementia that appear later in the course of disease in approximately 30% of patients 
(Aarsland & Kurz, 2010).  
 Dementia with Lewy bodies (DLB) is the second most common cause of 
dementia after AD (Goedert et al, 2001), and is characterized by dementia, hallucinations  
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Figure 0-1-1: Degeneration of Substantia Nigra in PD  
 
 
 
 
 
 
 
 
Figure 1-1: Degeneration of Substantia Nigra in PD (A) Images of midbrain 
sections of a neurologically healthy control (left), and a PD patient (right). In PD 
midbrain section, pigmented neurons of substantia nigra (black arrowheads) are 
severely reduced as a result of neurodegeneration. (B) Immunohistochemistry 
images of midbrain tissue stained with an α-syn antibody. At the left, a pigmented 
dopaminergic neuron with normal appearance is shown. At the right, a LB in a 
pigmented cell, and a proximal Lewy neurite (LN) are shown. Images kindly 
provided by Mr. John Robinson (Center for Neurodegenerative Disease Research, 
PA). Scale bar: 50µm. 
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as well as parkinsonian symptoms such as bradykinesia and rigidity. Multiple system 
atrophy (MSA) is a terminal neurodegenerative disorder, causing autonomic nervous 
impairment, parkinsonism and cognitive dysfunction. Individuals diagnosed with MSA 
have an average life span of 8 years only (Bower et al, 1997). As in PD, there are no 
treatments available to slow down or stop the progression of DLB and MSA.  
 The diseases mentioned above, as well as several others, such as: a subtype of 
AD (Lewy body variant of Alzheimer‟s disease) and neurodegeneration with brain iron 
accumulation type 1 (NBIΑ-1), have one major commonality: the presence of insoluble 
inclusions composed of the protein alpha-synuclein (α-syn) (Goedert, 2001; Neumann et 
al, 2000). The pathological hallmarks of PD are Lewy bodies (LBs) and Lewy neurites 
(LNs), which are fibrillar α-syn inclusions found in neuronal soma and neuritic processes 
respectively (Spillantini et al, 1997). The presence of LBs and LNs is correlated to 
functional deficits and cell loss observed in synucleinopathies: in PD LBs and LNs are 
common in brainstem particularly in SNc, in DLB, LBs are found in cortical areas and in 
MSA, α-syn accumulations, namely glial cytoplasmic inclusions (GCIs) are widely 
distributed among oligodendrocytes in affected regions (Spillantini, 1999). The presence 
of these inclusions in all these diseases and the connection between their predilection 
sites and disease symptoms strongly implicate α-syn aggregation with disease 
pathogenesis. Moreover, mutations in α-syn, namely A53T, E46K and A30P or α-syn 
gene locus multiplications, that may directly or indirectly promote α-syn aggregation 
cause familial PD (Kruger et al, 1998; Polymeropoulos et al, 1997; Singleton et al, 2003; 
Zarranz et al, 2004)., supporting that α-syn aggregation is a causative factor in disease 
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pathogenesis Therefore, these neurodegenerative diseases are collectively referred as 
“synucleinopathies” (Goedert & Spillantini, 1998). 
1.2 α-Synuclein  
α-Synuclein is a 140 amino acid protein highly expressed in central nervous 
system neurons, such that it constitutes 1% of total soluble brain protein (Iwai et al, 
1995). It can also be found at high levels in other tissues such as bone marrow and 
erythrocytes (Scherzer et al, 2008). The protein includes a N-terminal region composed 
of KTGEGV repeat sequences (Maroteaux et al, 1988), a hydrophobic central region 
(Ueda et al, 1993; Weinreb et al, 1996), and a negatively charged C-terminal region 
(Crowther et al, 1998). 
Recombinant α-Syn can form fibrillar aggregates in vitro, in a nucleation and 
concentration dependent manner (Conway et al, 1998; Wood et al, 1999). These 10-19nm 
wide fibrils are typical amyloid: insoluble, protease K resistant and rich in antiparallel β-
pleated sheet structure (Conway et al, 1998; Conway et al, 2000; Giasson et al, 1999). 
Fibrils made of purified recombinant α-syn are both ultrastructurally and biochemically 
very similar to the α-syn immunoreactive fibrils found in LBs (Conway et al, 2000; 
Giasson et al, 1999), which may indicate that LB formation is a process primarily driven 
by α-syn fibrillization. It has been shown that PD-linked α-syn mutations A53T and 
E46K increase the rate of fibrillization in vitro (Choi et al, 2004; Conway et al, 1998). In 
addition, α-syn locus multiplications found in familial cases of PD, may increase 
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intracellular α-syn concentration and thus the rate of fibrillization. The PD-linked A30P 
mutation does not affect the rate of fibrillization in vitro (Conway et al, 1998).  
The central, hydrophobic region of α-syn is initially referred as Non-amyloid 
component (NAC) domain, since it was first purified along with amyloid plaques from 
brains of AD patients. However, more recent studies demonstrated that α-syn does not 
co-aggregate with amyloid-β in extracellular space (Bayer et al, 1999), and the co-
purification of NAC domain was likely due to a contamination by intracellular LBs, 
which are common in AD stricken brain tissues. NAC region spans the aminoacids 71-82 
and gives α-syn the ability to form amyloid fibrils (Giasson et al, 2001). This region can 
fibrillize by itself at a much faster rate indicating that the remainder of the protein does 
not significantly contribute to fibrillization process (Giasson et al, 2001).  
N-terminus of α-syn is believed to be involved in membrane interaction and 
studies on α-syn crystal structure showed that this region, which is natively unfolded, 
assumes an alpha-helical conformation when bound to lipid membranes (Davidson et al, 
1998; Mihajlovic & Lazaridis, 2008). Although PD-linked α-syn mutation A53T is not 
shown to affect lipid binding, other PD-linked mutations modify this interaction in 
opposite ways, such that A30P mutation reduces lipid binding, whereas E46K promotes it 
(Choi et al, 2004; Perrin et al, 2000). These conflicting results may suggest that lipid 
binding ability of α-syn does not play a direct or pivotal role in α-syn pathogenesis. 
C-terminus of α-syn is highly acidic due to the abundance of glutamate residues 
and it is a evolutionarily less conserved part of the protein (Maroteaux et al, 1988). C-
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terminally truncated α-syn aggregates faster in vitro (Murray et al, 2003) and truncated α-
syn can be found in LBs, however it not clear if this modification occurs after 
aggregation, post-translationally before aggregation, or if these truncated α-syn species 
are alternative splicing variants (McLean et al, 2012). 
α-Syn has two homologs in vertebrates: β- and ɣ-synuclein (Ninkina et al, 1998; 
Tobe et al, 1992). β-synuclein is highly homologous to α-syn but lacks the majority of the 
NAC domain, hence the ability to form amyloid fibrils. β-synuclein is not observed in 
any type of α-syn inclusions and believed to have an inhibitory effect on α-syn 
aggregation (Hashimoto et al, 2001). Mutations in β-syn gene have been linked to 
familial form of DLB (Ohtake et al, 2004). ɣ-Synuclein exhibits less homology to other 
synucleins, and there is no evidence indicating that it plays a role in synucleinopathies. 
However, it has shown to be overexpressed in breast tumors and therefore can be used as 
a marker for tumor progression (Bruening et al, 2000).  
In neurons, α-syn is localized to synapses, and found in close proximity to 
synaptic vesicles (Iwai et al, 1995). α-Syn is delivered to synapses later in development 
(in about 18 weeks of gestation, (Galvin et al, 2001b)) and genetic ablation of α-syn does 
not impair synaptogenesis indicating that this protein does not play a vital role in 
formation of synapses (Abeliovich et al, 2000). 
α-Syn knockout (KO) animals show only minor phenotypic changes (Abeliovich 
et al, 2000), and comparable results were obtained from α-syn/β-syn double KO studies 
suggesting that the failure to detect dramatic changes is not due to compensatory effects 
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of the other neural synuclein protein (Chandra et al, 2004). Similarly, overexpression of 
α-syn in murine models did not cause overt physiological changes, apart from secondary 
effects of synaptic or neuronal degeneration accompanied by α-syn aggregation (Giasson 
et al, 2002). Therefore, there is no consensus on physiological function of α-syn. 
Nevertheless; these studies provided evidence on possible functions of α-syn. 
Most α-syn ablation studies showed effects, albeit subtle, in synaptic function. 
Since α-syn binds membranes, and found in close association with synaptic vesicles, it 
was proposed that it may regulate synaptic transmission. Indeed α-syn KO mice have 
shown to possess a reduced pool of reserve synaptic vesicles (Cabin et al, 2002) and α-
syn overexpression in PC12 and chromaffin cells results in a limited increase in docked 
synaptic vesicles suggesting that a late step in exocytosis is affected (Larsen et al, 2006). 
Perhaps the most convincing evidence about α-syn function was presented in a study 
from α-syn/β-syn /ɣ-syn triple KO mice, which suggested that α-syn acts as a synaptic 
chaperone assisting presynaptic SNARE complex assembly (Greten-Harrison et al, 
2010). This finding is supported by prior evidence indicating that α-syn has homology to 
chaperone proteins, have in vitro chaperone activity and can rescue neurodegeneration 
observed in mice lacking chaperone-like CSPα protein (Chandra et al, 2005). 
Alternatively, it has been proposed that α-syn may regulate dopamine transporter 
(DAT) delivery to plasma membrane, inhibit tyrosine hydroxilase (TH) (Lee et al, 2001; 
Perez et al, 2002; Wersinger & Sidhu, 2003), and α-syn phosphorylation, which is mostly 
observed under pathological conditions, upregulates TH activity (Wu et al, 2011). Thus, 
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α-syn may play a role in determining intracellular dopamine levels but the physiological 
and pathological relevance of this is yet to be determined. 
Moreover, studies indicate that α-syn may regulate activities of other enzymes. 
Synuclein family members are potent inhibitors of phospholipase D2 in vitro (Jenco et al, 
1998; Payton et al, 2004), and they may also inhibit protein kinase C  (Narayanan et al, 
2005; Ostrerova et al, 1999). However, more recent studies failed to demonstrate 
biological relevance of these findings and link them to the role of α-syn in pathogenesis. 
1.3 Role of α-syn in pathogenesis 
Similar to its normal function, the role of α-syn in pathogenesis is not completely 
understood. However, evidence suggests that α-syn aggregation plays a significant role in 
pathogenesis. Firstly, α-syn aggregates are found in all synucleinopathies and they are 
enriched in regions in brain regions associated with symptoms (Trojanowski & Lee, 
2001). Secondly, two of three PD-linked α-syn mutations A53T and E46K increase α-syn 
aggregation in vitro (Choi et al, 2004; Conway et al, 1998), and the remaining mutation, 
A30P, may indirectly promote aggregation by reducing lipid bound α-syn and increasing 
the concentration of free α-syn that can readily aggregate (Perrin et al, 2000). Moreover, 
in murine models of synucleinopathies overt phenotype and cell loss are typically 
observed after formation of insoluble α-syn aggregates (Giasson et al, 2002; Luk et al, 
2012; Trojanowski & Lee, 1999), although more subtle phenotypic changes may be 
observed prior to initiation of neurodegeneration and LB-like α-syn aggregate formation 
(Hashimoto et al, 2003). These aggregates may impair cellular function and cause cell 
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death through a wide variety of mechanisms, they could sequester important cellular 
proteins or vesicles, disrupt cytoskeleton, impair protein trafficking or other vital cellular 
processes. It is unlikely that aggregation of α-syn confers its toxicity through sequestering 
soluble α-syn thereby preventing its normal function, since none of α-syn KO models 
exhibited PD-like phenotype. 
An alternative, but not mutually exclusive, hypothesis is that soluble α-syn 
oligomers or protofibrils are toxic to cells. Tubular, annular or spherical multimeric α-syn 
structures have been observed in vitro (Ding et al, 2002; Volles et al, 2001) and it has 
been suggested that annular α-syn structures may act as pores in membranes, such as 
mitochondrial membrane, causing mitochondrial dysfunction, oxidative stress and 
apoptosis via cytochrome c release. (Volles et al, 2001). Still, although oxidative stress 
and mitochondrial dysfunction are very strongly implicated in pathogenesis of 
synucleinopathies, particularly PD (Jenner & Olanow, 1996; Vila et al, 2008), the 
evidence implicating pore-like oligomeric α-syn structures with these defects is sparse 
and such structures are yet to be detected in cells, or in vivo. Apart from that, the results 
of several cell culture studies indicate that α-syn oligomers may also block protein 
degradation by lysosomes and proteasome (Cuervo et al, 2004; Martinez-Vicente et al, 
2008; Snyder et al, 2003), which may indirectly cause toxicity. 
Additionally, the extent of post translational α-syn modifications are shown to be 
dramatically increased in synucleinopathies and it was suggested that they may play a 
role in pathogenesis. While α-syn is scarcely phosphorylated at S129 in neurons, LBs and 
other α-syn aggregates are heavily phosphorylated. In addition, α-syn ubiquitination is 
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only observed in the presence of α-syn aggregation (Fujiwara et al, 2002; Kuzuhara et al, 
1988). Nitrated α-syn is found in LBs and other α-syn aggregates, whereas it cannot be 
detected in healthy cells (Paxinou et al, 2001). None of these modifications are required 
for α-syn aggregation in vitro and in vivo (Michell et al, 2007; Sampathu et al, 2003), and 
although the evidence about the effects of these modifications on kinetics of α-syn 
aggregation is somewhat conflicting (Lee et al, 2008; Meier et al, 2012; Souza et al, 
2000; Yamin et al, 2003), the trend is that they increase the rate of aggregate formation or 
stabilize the aggregates. Although it is possible that α-syn is more commonly modified in 
disease state, it is also very likely that newly synthesized α-syn is continuously modified 
but these modified forms are rapidly cleared and not readily detected unless they gain 
resistance to clearance by being recruited to pathological aggregates.  
1.4 Protein degradation pathways  
Protein degradation pathways (Pdps) are cellular mechanisms evolved to identify, 
and hydrolyze proteins that are needed to be removed from cells. Pdps function in post-
translational regulation of protein levels, removal of damaged, misfolded, or aggregated 
proteins, as well as disassembly of proteins to acquire amino acids during starvation. 
There are two major Pdps in eukaryotes that take part in degradation of intracellular 
proteins. Ubiquitin proteasome system (UPS) and autophagy-lysosome pathway (ALP) 
(Rubinsztein, 2006). UPS is typically involved in degradation of short lived, cytoplasmic 
or nuclear proteins. In UPS, target protein is tagged by a chain of small proteins called 
ubiquitin. The ubiquitin chain is attached to lysine residue on the target protein via an 
isopeptide bond, and it is recognized by the 19S regulatory subunit of the proteasome. 
11 
 
This 19S proteasome takes part in removal of ubiquitin tag and unfolds the target protein, 
so that it can access the active sites of the proteases buried in barrel shaped 20S 
proteasome catalytic subunit (Bedford et al, 2010). Localization of active sites of the 
proteasome inside a barrel shaped protein which can be accessed only through a narrow 
channel, minimizes the possibility of uncontrolled degradation of surrounding proteins by 
the proteasome, however it creates a restriction such that proteins needs to be unfolded 
before degradation. This restriction creates two problems, firstly large aggregates cannot 
be directly degraded by proteasome, secondly misfolded proteins or oligomers which are 
resistant to unfolding can block the entry to proteasome and inhibit its function.   
Chaperone mediated autophagy (CMA), microautophagy, and macroautophagy 
are three constituents of ALP and their commonality is that they involve translocation of 
cytoplasmic substrates to lysosomes or autophagolysosomes for degradation. In CMA, 
cytoplasmic proteins that carry the KFERQ motif are recognized by the chaperone Hsp70 
and translocated to lysosomes through Lamp2a channels (Cuervo, 2010). Similar to UPS, 
this pathway necessitates unfolding of proteins and can be blocked by protein aggregates. 
Approximately 30% of cytoplasmic proteins contain KFERQ motif and believed to be 
degraded by CMA (Cuervo, 2010). Microautophagy is the least understood and studied 
type of autophagy and is believed to occur by engulfment of small portions of cytoplasm 
directly by lysosomes. Neither its exact function, nor the extent of its role in total cellular 
protein degradation is clearly understood (Santambrogio & Cuervo, 2011). 
Macroautophagy is the most prominent type of autophagy and therefore usually simply 
referred as autophagy. In autophagy, a number of proteins orchestrate formation of a  
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Figure 1-0-2: Simplified schematic diagram of mammalian autophagy  
 
 
 
 
 
 
 
 
Figure 1-2: Simplified schematic diagram of mammalian autophagy With the 
activation of autophagy, pre-autophagosomal structure (PAS) is formed by 
assembly of autophagy related atg proteins. PAS primers formation of cup shaped 
membranous phagophore, which is characterized by the enrichment of membrane 
bound LC3-II. While phagophore expands by recruitment of additional lipids, it 
engulfs the target it recognizes via adaptor proteins, such as p62 that binds ubiquitin 
and LC3. With the complete engulfment of the substrate, a closed, double 
membrane structure called autophagosome is formed. While autophagosomes are 
transported to lysosome rich perinuclear areas on microtubule tracks, they fuse with 
endosomes such as CD63 containing multivesicular bodies, forming amphisomes. 
Amphisomes eventually fuse with lysosomes that are decorated with Lamp1. This 
fusion results in formation of autophagolysosomes, in which lysosomal proteases 
degrade the autophagy substrates, p62 and LC3 located in the inner membrane of 
the autophagosome. 
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membranous body called pre-autophagosomal structure (PAS). PAS formation is 
followed by extension of lipid core to form a cup shaped membranous structure called the 
phagophore. The origin of the lipids that form this structure is debated but it is believed 
that endoplasmic reticulum is the major source, while golgi, plasma membrane, 
mitochondrial membrane and free lipids in cytoplasm may be contributing (Axe et al, 
2008). Phagopore, which can be identified by phosphoethanolamine conjugated 
microtubule binding protein light chain 3–II (LC3-II) which decorates it, expands by 
progressive recruitment of additional lipids. Although it was initially thought that 
autophagy is an unspecific process, now significant evidence supports that prior to and 
during phagopore formation, adaptor proteins bind autophagy substrates and LC3-II, 
thereby recruiting newly forming autophagosome to the substrate to be degraded. One of 
the best examples of such adaptors is, the protein SQSTM-1/p62 which has both ubiquitin 
and LC3 binding sites therefore can tag ubiquitinated protein aggregates for autophagic 
degradation (Bjorkoy et al, 2005). Interestingly, PD-linked genes parkin and Pink-1 
havealso shown to play a role in specific degradation of damaged mitochondria via 
autophagy (Narendra et al, 2008; Vives-Bauza et al, 2010), a process referred as 
mitophagy. When both ends of phagophore fuse, engulfing the substrate, a double-
membrane autophagosome forms. Autophagosomes are transported to lysosomes in a 
microtubule dependent manner and during this process, they can also fuse with other 
cytoplasmic vesicles such as late endosomes, or multivesicular bodies, to form 
amphisomes (Eskelinen et al, 2005). The events that take place between autophagosome 
formation and autophagosome/lysosome fusion are called autophagosome maturation. 
Autophagosome/lysosome fusion results in formation of autophagolysosomes and 
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proteolytic degradation of the substrate, as well as LC3-II and p62 that are located in the 
inner membrane of the autophagolysosome. This event results in release of degradation 
products for use as building blocks, and recycling of undegraded components such as 
proteins located in outer membrane of autophagosomes, and proteolytic lysosomal 
enzymes, consequently leading to clearance of autophagosomes from cytoplasm. 
Autophagy, particularly during PAS and autophagosome formation steps, is orchestrated 
by a family of autophagy related proteins. In addition to the proteins that play a role in 
relaying initiation signals to autophagic machinery, such as ULK1 and beclin-1, proteins 
that are vital in autophagic process such as atg5, atg7 are often genetically ablated to 
eliminate autophagic activity in vitro or in vivo (Hara et al, 2006; Komatsu et al, 2006). 
Autophagy is a tightly regulated process, particularly mTOR pathway is a major regulator 
of autophagy. Reduction in availability of amino acids, glucose, ATP/AMP ratio or 
growth factors inhibit mTOR activity, thereby activating autophagy. Among these 
factors, amino acid starvation or direct pharmaceutical inhibition of mTOR with drugs, 
such as rapamycin, are the most commonly used methods to activate autophagy 
(Ravikumar et al, 2010). Autophagy can also be regulated through mTOR independent 
mechanisms, such as calpain activity, Ca
+2
 levels, and IP3 levels (Harr & Distelhorst, 
2010). Furthermore, it has also been shown that proteolytic stress caused by proteasome 
dysfunction, oxidative stress, aging, certain disaccharides and spingolipids are among 
those that can affect autophagic activity (Ravikumar et al, 2010). 
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1.5 Pdps and neurodegeneration 
There are several lines of evidence implicating Pdps with neurodegerative 
diseases. Firstly, majority of these diseases exhibit Pdp pathology such as accumulation 
of autophagic vacuoles in AD and PD (Boland et al, 2008; Higashi et al, 2011). 
Furthermore, inhibition of these pathways via pharmaceutical means or genetic ablation 
of important Pdp genes are neurotoxic, suggesting that Pdp inhibition may be a 
mechanism through which primary defects indirectly lead to cell death in 
neurodegenerative diseases. Virtually all neurodegenerative diseases involve aggregation 
of disease specific proteins, such as α-syn in synucleinopathies, tau/amyloid-β in AD, and 
polyglutamine expanded huntingtin in huntington disease. Thus, impaired Pdp function 
may also be an initiating factor in pathogenesis since it has been shown that in the 
absence of Pdp function, cells can form aggregates similar to the ones observed in 
neurodegenerative diseases. However, it is not clear why different proteins aggregate 
only in certain brain regions in different neurodegenerative diseases if Pdp impairment 
played a strictly causative role in the pathogenesis. Therefore it is still debated whether 
impairment of Pdp function is mostly a result of disease pathology, or it plays a 
significant role in the pathogenesis. 
As aforementioned, neurodegenerative diseases involve protein inclusions and 
autophagy was shown to be able to degrade inclusions of some of such proteins including 
huntingtin. Since as in PD, there is evidence that protein inclusions contribute to 
pathology also in other neurodegenerative diseases, activation of autophagy was offered 
as a therapeutic approach for such diseases. This topic will be discussed in section 1.8. 
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1.6 Pdps and α-syn degradation 
As its function and role in pathology, the degradation of α-syn was also a topic 
that has not been completely clarified. However, recent in vivo and in vitro studies shed 
light on this matter and it is now widely accepted that natively unfolded α-syn, 
particularly when phosphorylated, is mainly degraded by the proteasome in a ubiquitin 
independent manner (Ebrahimi-Fakhari et al, 2011; Machiya et al, 2010). However, when 
α-syn levels increase and α-syn forms soluble oligomers that cannot access catalytic sites 
of the proteasome because of their size and inability to be unfolded, autophagy plays a 
more important role in their degradation. α-Syn has a CMA motif and can be degraded by 
this pathway, but similar to proteasome, CMA fails to degrade α-syn when it forms stable 
oligomers (Cuervo et al, 2004). 
Unlike soluble α-syn species, degradation of insoluble α-syn aggregates is not 
well documented. This is mainly due to lack of in vitro models which faithfully 
recapitulate formation of highly insoluble pathological α-syn aggregates. Although a 
number of studies indicate that autophagy can clear α-syn aggregates (Spencer et al, 
2009; Wong et al, 2008)and elsewhere), the structures identified as α-syn aggregates in 
these studies are often fundamentally different than bona fide α-syn aggregates observed 
in disease stricken brain tissues. This topic will be further discussed in section 1.7. 
1.7 Models of synucleinopathies  
Due to prominence of α-syn aggregates in synucleinopathies, a large number of in 
vitro and in vivo models of α-syn aggregation were developed in the last decade. Unlike 
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many aggregate prone proteins, such as poly glutamine expanded Htt, α-syn does not 
readily aggregate when overexpressed. Particularly in cell based in vitro models, α-syn 
remains soluble even at very high expression levels and additional manipulations such as 
exposure to oxidative, nitrative or proteolytic stress are required to induce α-syn 
aggregation (Lee et al, 2002; McLean et al, 2001; Paxinou et al, 2001). Apart from 
having a relatively low efficiency, this approach has another limitation: since the 
manipulations that are needed to generate α-syn inclusions affect Pdp function, such 
models are not ideal to study degradation of these aggregates by Pdps, or their effect on 
Pdp function. Co-overexpression of α-syn with snyphillin-1, which is shown to colocalize 
with LBs, results in formation of inclusions that contain α-syn in a small percentage of 
the cells (Engelender et al, 1999). In addition, overexpression of α-syn tagged with GFP 
also causes minor α-syn aggregation (McLean et al, 2001). The main caveat with these 
two models is the possibility that α-syn is “packaged” amorphously into the inclusions 
whose formation is driven by external factors, such as GFP aggregation and aggresome 
response (Kopito, 2000). On the other hand, purified α-syn can form aggregates that 
share similar ultrastructure with LBs and LNs, indicating that formation of these highly 
organized aggregates is likely driven by α-syn itself.  
Although insoluble α-syn aggregates are observed in in vivo models of α-syn 
overexpression, there is evidence suggesting these models may not accurately 
recapitulate human disease. First of all, substantia nigra pars compacta (SNc), which is a 
predilection site of the aggregates in PD brain, is often resistant to aggregate formation 
and cell loss, whereas many regions that are not particularly affected in human disease, 
such as spinal cord, show significant pathology (Giasson et al, 2002). Secondly, in 
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several studies, the α-syn immunoreactive structures identified as aggregates are small 
puncta, which are neither fibrillar nor phosphorylated and there is no convincing 
biochemical data showing that they are insoluble. It may be highly misleading to draw 
conclusions about potential pathways that can clear pathological LB-like α-syn 
aggregates based on such models. 
Although α-syn overexpression can cause PD in humans, attempting to replicate 
disease conditions in mice with α-syn overexpression may cause artifacts such as 
formation of amorphous inclusions before LB-like, amyloid aggregates can form. Indeed, 
such a study describes the α-syn immunopositive structures as: “less circumscribed, are 
present in the nucleus, and lack fibrillar components” moreover, there were no data 
shown about the solubility or phosphorylation state of these accumulations, indicating 
that these structures do not represent pathological LBs (Masliah et al, 2000). In addition, 
an inducible α-syn mouse model from our lab (Lim et al, 2011) showed that younger 
mice (12 month-old) had small, partially phosphorylated, soluble α-syn immunoreactive 
puncta, that can be cleared from certain brain regions after cessation of α-syn expression. 
On the other hand, aged mice (20 month-old) had larger, insoluble, highly 
phosphorylated α-syn aggregates that are much more similar to LBs. Furthermore, α-syn 
puncta in younger mice were not associated with cell loss, whereas aged mice had overt 
cell loss on predilection sites of LB-like α-syn aggregates (Lim et al, 2011). These data 
indicate that α-syn overexpression may initially cause formation of α-syn 
immunoreactive structures which are fundamentally distinct from LBs, while formation 
of α-syn accumulations that could be used as LB-models necessitates more time. It could 
be speculated that this “lag period”, is the underlying reason for the difficulty of  
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generating cell-based models of LB formation. Elimination of this lag period would 
enable LB-like aggregate formation in cell culture, without generation of other types of, 
and potentially misleading α-syn accumulations.  
Recently, we have shown that intracellular, LB-like α-syn aggregates can be 
efficiently “seeded” by introduction of exogenous α-syn fibrils (Pffs) to cultured cells 
that express α-syn, including primary neurons (Figure 1-3) (Luk et al, 2009; Volpicelli-
Daley et al, 2011). This method is extremely efficient such that more than 80% of the 
cells in the culture eventually form α-syn aggregates, more importantly; the seeded 
aggregates that form after transduction are remarkably similar to LBs and LNs in many 
aspects such as of their biochemical properties, ultrastructure, and post-translational 
modifications. Moreover, introduction of Pffs per se, is not toxic and does not affect 
function of Pdps, rendering these models ideal to study the effect of α-syn aggregates on 
Pdps and cell viability, as well as the potential Pdps that can degrade them. Our cellular 
models of α-syn seeding and recruitment of endogenous α-syn to yield LB-like  
aggregates may replicate key aspects of synucleinopathies, as several recent lines of 
evidence suggest that the spreading of amyloid protein pathology, such as seen with α- 
syn in PD, may result from the neuronal release and uptake of extracellular seeds (Angot 
et al, 2010; Brundin et al, 2010; Luk et al, 2012; Soto, 2012). Indeed, these recent 
findings help explain prior observations about linear, non-random, spread of α-syn 
pathology (Braak et al, 2003) , and the appearance of LBs in neuronal grafts implanted 
into the brains of PD patients (Kordower et al, 2008). 
There are also models of synucleinopathies which are not dependent of α-syn 
aggregate formation: Since the most prominent pathology, and the underlying reason of 
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Figure 0-3: Pre-formed fibril transduction model of α-syn aggregation  
 
 
 
 
 
 
Figure 1-3: Pre-formed fibril transduction model of α-syn aggregation (A) A 
schematic representation of pre-formed fibril (Pff) transduction method. 
Recombinant α-Syn (shown in red) is allowed to form fibrils, which are sonicated 
to form Pff fragments. Fragmented Pffs (in neurons) or Pff-lipid complex 
generated by incubation of fragmented Pffs with lipid-based tranduction reagent 
(in non-neuronal cells), are added to cell media. Both in neuronal and non-
neuronal cells, transduced Pffs gain entry to cell and recruit endogenously 
expressed α-syn (shown in green) leading to formation of LB and LN-like α-syn 
aggregates. (B) Phospho-α-syn (p-α-syn, green) IF images showing: (Left) A high 
magnification view of a Pff-td HeLa cell with a LB-like aggregate. Note the 
dense core, and radiating filamentous structures. (Middle, right) Pff-td neurons 
showing both LB-like somatic aggregates and LN-like neuritic aggregates.  
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motor symptoms is the loss of dopaminergic neurons in substantia nigra in PD, toxin-
mediated ablation of these cells has been used to generate α-syn independent models of 
PD in several organisms ranging from flies to non-human primates. The most common 
toxins used are the by-product of an illicit drug synthesis attempt MPTP, the herbicide 
paraquat, and the natural insecticide rotenone. All these toxins are associated with 
increased risk of PD, in humans (Gorell et al, 1998; Langston et al, 1999; Liou et al, 
1997) and inhibit mitochondrial complex I thereby causing selective degeneration of 
nigrostriatal dopaminergic neurons (Betarbet et al, 2000). Although some studies report 
that paraquat and rotenone increase α-syn expression induce formation of α-syn 
aggregates (Betarbet et al, 2000; Manning-Bog et al, 2002). MPTP monkey model, which 
is the gold-standard of toxin-based models, and brains of MPTP-intoxicated patients do 
not have α-syn aggregates (Forno et al, 1993) which suggest that mitochondrial 
dysfunction/oxidative stress mediated dopaminergic cell loss may be downstream of α-
syn aggregate formation.  
1.8 Proposed therapeutic approaches for synucleinopathies  
Currently, only therapies available for synucleinopathies are the ones aiming to 
alleviate parkinsonian motor symptoms of these diseases. Although these symptomatic 
treatments such as levodopa, MAO inhibitors or deep brain stimulation are very helpful 
particularly in the earlier stages of the disease, they tend to be less effective at more 
advanced stages and they do not improve common non-motor symptoms such as 
cognitive decline observed particularly in DLB. In addition, such therapies do not slow 
down autonomic dysfunction in MSA which renders the disease lethal. Therefore, a 
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therapeutic strategy which would stop or slow down the disease progression is required. 
Stem cell based therapies are promising (Schwarz & Schwarz, 2010), but are far from 
ready to be employed for routine clinical use. Furthermore, transmissible nature of α-syn 
pathology may dramatically limit the success rate of such therapies.  
For reasons we discussed before, reduction of α-syn aggregation is one of the 
most commonly studied potential therapeutic approach. There are multiple ways to elicit 
a decrease in α-syn aggregates: reduction of α-syn synthesis, inhibition of α-syn 
aggregation, or induction of clearance of α-syn aggregates. α-Syn expression may be 
reduced by delivery of anti-α-syn siRNAs or activation of Pdps that degrade α-syn. 
Although there is no convincing human data on this subject, based on the findings on 
mouse models (Abeliovich et al, 2000), it is plausible to expect that a decrease in α-syn 
levels will not have a detrimental effect on human brain function. However, this approach 
is primarily preventative and although it may have significant benefits before formation 
of the aggregates, its effectiveness may be limited after the symptoms of the disease 
manifest. Inhibitors of α-syn aggregation are also investigated as potential treatment 
options (El-Agnaf et al, 2004), however, unlike inhibiting an enzymatic function, 
inhibiting interaction of large protein surfaces (for α-syn, hydrophobic NAC region) has 
proven to be very challenging. Because of the nature of the likely mechanism of 
inhibition, i.e. binding NAC region and blocking further α-syn binding by steric 
hindrance, such inhibitors should be relatively large, and be used at near-equimolar ratios 
with α-syn, which makes them poor drug candidates. It was suggested that β-synuclein 
inhibits α-syn aggregation (Hashimoto et al, 2001), but the evidence is not compelling 
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enough to render β-syn expression a viable therapeutic approach, particularly considering 
the technical challenges of gene therapy. If possible, removal of pre-existing aggregates 
could perhaps be the most practical therapy for synucleinopathies, since it would not 
necessitate diagnosis of the disease before manifestation of clinical symptoms and it 
could be beneficial to the patients at more advanced stages of the disease. A small 
number of studies claim benefit of immunotherapy in mouse α-syn overexpression 
models, however, these studies were based on the aggregation model we previously 
discussed (Masliah et al, 2000), i.e. the α-syn accumulations observed in this model were 
vastly different from LBs or LNs. Moreover, while the first study based on this model 
claimed that immunotherapy clears intracellular α-syn accumulations (Masliah et al, 
2005) the second study based on the same mouse model, but carried out after the advent 
of α-syn transmission evidence (Bae et al, 2012) attributed the effect of the 
immunotherapy to clearance of extracellular α-syn seeds. Perhaps, this example may 
emphasize the vital importance of accurate models of synucleinopathies. Finally, possibly 
the most discussed approach to remove α-syn aggregates is activation of autophagy, 
particularly since it has been shown that aggregates of several neurodegenerative disease 
related proteins can be cleared via this pathway (Bjorkoy et al, 2005; Williams et al, 
2006). However, as discussed before, α-syn aggregation models used in such studies may 
not fully recapitulate α-syn aggregation in synucleinopathies and the limited effect 
observed in a number of such studies may reflect indirect reduction of aggregation due to 
reduction of soluble α-syn, and/or degradation of non-fibrillar α-syn deposits which are 
not representative of LBs or LNs. It is very important to note that the study that provides 
the bulk of the in vivo evidence on the role of autophagy in degradation of α-syn 
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“aggregates” is based on the controversial α-syn accumulation model that was used for 
the aforementioned α-syn immunotherapy studies (Spencer et al, 2009). Although 
activation of autophagy may appear to be a plausible approach, recent findings showing 
that such manipulations in cells with impaired autophagosome clearance may be 
detrimental (Boland et al, 2008; Wong & Cuervo, 2010; Zhang et al, 2011) emphasizes 
the fact that this strategy may lead to undesirable outcomes, and before offering it as a 
viable approach one must be precautious enough to investigate if these aggregates can 
indeed be cleared by autophagy and if they affect autophagy function using the most 
accurate α-syn aggregation models available. 
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Chapter 2: Optimization of Pff Transduction in HEK293 Cells 
2.1 Abstract 
Faithful models of α-syn aggregation are indispensible to study LBs, and their 
role in pathogenesis. We previously introduced a model of α-syn aggregation in which 
intracellular LB-like α-syn inclusions accumulate after cationic-lipid assisted 
internalization of pre-formed α-syn fibrils into α-syn-expressing cells. However, a 
limitation of the model was that only a minority of the treated cells developed aggregates, 
decreasing the sensitivity of the biochemical analyses that aim to identify the cellular 
impact of α-syn aggregates. Here, we demonstrate that the model can be significantly 
improved by use of truncated Pffs and mutant α-syn expression. We show that, when 
seeded with c-terminally truncated Pffs, A53T mutant α-syn has a higher propensity to 
form aggregates compared to both wild-type and other PD-linked α-syn mutants, such 
that almost 80% of cells formed aggregates after transduction of A53T mutant a-syn 
expressing cells. However, even though the amount of aggregated α-syn is dramatically 
increased in the optimized system, cationic-lipid reagent is still needed to attain sufficient 
α-syn aggregation. We believe that our findings rendered the Pff-transduction model a 
better in vitro tool to study synucleinopathies, and we hope that it will be helpful in our 
efforts to gain an insight into the role of α-syn aggregates in neurodegenerative disease.  
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2.2 Introduction 
To understand the mechanism of LB formation and its possible role in 
pathogenesis, numerous in vitro models of α-syn aggregation has been generated. 
However, it has not been possible to model LB formation in various cell lines by simple 
α-syn overexpression and this may due in part to the fact that α-syn is highly soluble and 
exist normally as an unstructured protein. Through use of different methods including co-
overexpression with other proteins, exposure to oxidative stress, nitrative insult (McLean 
et al.,2001 ; Paxinou et al., 2001 ; Lee et al., 2002 and elsewhere), several other groups 
succeeded in generation of α-syn aggregates only in a small percentage of cells. In 
addition to their scarcity, those aggregates did not show important characteristics of LB, 
such as, containing fibrillar α-syn, being ubiquitinated (Kuzuhara et al., 1988) and 
phosphorylated (Fujiwara et al., 2002). The need for a more efficient model that would 
recapitulate α-syn aggregate formation in vitro was met when we developed a novel 
method for introducing preformed α-syn fibrils (Pffs) into cells. α-Syn readily fibrillizes 
in test tube (Conway et al., 1998 ; Giasson et al., 1999) and these amyloid Pffs can be 
delivered to different cell types through a liposome mediated protein transduction 
method. Once they gain entry inside cells, Pffs are able to recruit endogenous α-syn into 
LB-like aggregates. This system creates unique opportunity to investigate whether or not 
intracellular α-syn aggregates affect cellular function. However, this model was limited in 
the sense that only 15-20% of transduced cells form large (>5µm in diameter) inclusions 
(Luk et al., 2009). A higher efficiency was required to biochemically determine the 
functional consequences of the inclusions on the cell and to test how pharmacological 
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manipulations can impact aggregate formation. We hypothesized that inclusion formation 
would be accelerated by use of disease associated mutant α-syn in our model.  
2.3 Results 
Improvement of Pff transduction efficiency by use of truncated Pffs and A53T 
mutant α-syn expression 
We have previously shown that when transduced with wild-type (wt) Pffs, 
approximately 40% of the cells that express wt α-syn form phosphorylated, insoluble α-
syn aggregates and only 15-20% of these cells form large (>5um in diameter) inclusions 
(Luk et al., 2009). However, a higher efficiency was required to biochemically determine 
the functional consequences of the inclusions on the cell and determine how 
pharmacological manipulations can impact aggregate formation. We hypothesized that 
inclusion formation would be accelerated by transducing cells that express A53T mutant 
α-syn, that is linked to familial PD and has accelerated fibrillization in vitro (Conway et 
al, 1998). We also wanted to test if Pffs generated from c-terminally truncated α-syn 
(amino acids 1-120), which has been shown to fibrillize faster in vitro (Murray et al, 
2003), will result in increased transduction efficiency. To test these possibilities, HEK293 
cell lines that express comparable levels of wt and A53T mutant α-syn were transduced 
with wt Pffs or 1-120 truncated Pffs and inclusion formation was visualized using mAB 
81A which detects phosphorylated, aggregated forms of α-syn, including LBs in human 
brain tissue. As expected, we observed that cells expressing A53T mutant α-syn generate 
more pathology when transduced with both wt and truncated Pffs. Furthermore, truncated 
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Pffs seed more efficiently in both wt α-syn and A53T α-syn expressing cells (Figure 2-
1A, B). Overall, the 4.7-fold increase in transduction efficiency (16.7%±3.5% vs 78.5% 
±0.7%) was elicited using cells expressing A53T α-syn and 1-120 truncated Pffs for 
transduction. Our observations by IF was confirmed by immunoblotting, indeed, when 1-
120 and wt Pffs were compared in wt α-syn expressing cells, 1-120 truncated Pffs seeded 
dramatically more pathology (Figure 2-1C) and when 1-120 Pffs were used to transduce 
wt or A53T α-syn expressing cells, A53T expressing cells produced significantly higher 
pathology (Figure 2-1D) confirming our IF data. In particular when comparing wt and 
A53T cells, the differences in pathology were even more pronounced by IB supporting 
the IF observation that the aggregates are not only more frequent in A53T cells, but also 
larger in size. 
Our significant improvement on transduction efficiency enabled us to monitor 
previously unidentified effects of the α-syn inclusions, such as cytotoxicity and 
impairment of autophagic maturation as discussed in Chapter 4.  
Expression of PD-linked A30P or E46K mutant α-syn does not improve aggregate 
formation. 
Since PD associated A53T mutant α-syn produced more aggregates, we wanted to 
test if expression of other PD associated mutants such as A30P and E46K (Kruger et al, 
1998; Zarranz et al, 2004) would cause an increase in aggregate formation. We 
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Figure 4 Transduction efficiency is improved by mutant a-syn expression and use 
oftruncated Pffs  
 
 
 
 
 
Figure 2-1: Transduction efficiency is improved by mutant a-syn expression and 
use of truncated Pffs:(A) Immunofluorescence (IF) pictures showing HEK293 
cells stably expressing wild-type (wt) (left) or A53T (right) a-syn that were 
transduced with wt (top) or 1-120 truncated (bottom) a-syn Pffs, which are both 
myc tagged at c-terminus. Cells fixed after 48h of starvation and a-syn aggregates 
(red), Pffs (green), and nuclei (blue) were visualized with phospho-a-syn (p-a-syn), 
myc antibodies and DAPI respectively. 1-120 Pff transduced A53T a-syn cells 
generated the highest amount of pathology. (B) Quantification of IF data, n>400 
cells for each condition. (C) Immunoblot with p-a-syn, n-terminal a-syn (SNL4), 
myc, p62 and a-tub as loading control. When transduced with comparable amounts 
of Pffs, 1-120 transduced wt a-syn expressing cells generate significantly more 
pathology compared to wt a-syn transduced wt a-syn expressing cells. (D) IB with 
p-a-syn, c-terminal a-syn (Syn211), p62 and a-tub. A53T a-syn expressing cells 
generate more pathology when compared to wt a-syn cells. Together, these data 
indicate that use of A53T a-syn cells, and 1-120 truncated Pffs dramatically 
increases a-syn pathology [data from a minimum of 3 independent experiments, 
error bars +SEM.**denotes p<0.005 according to student‟s t test. Scale bars 
10um]. 
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Figure 2-0-5: E46K and A30P mutant α-syn expression does not increase aggregate formation  
 
 
 
 
 
 
 
 
 
 
Figure 2-2: E46K and A30P mutant α-syn expression does not increase 
aggregate formation (A,B) Naive HEK293 cells transiently transfected with wt 
and A53T, E46K, A30P mutant α-syn and transduced with 1-120 α-syn Pffs. (A) 
IF pictures showing p-α-syn aggregates (red). (B) IB picture showing α-syn 
expression and aggregated/ phosphorylated α-syn levels. Both IF and IB data 
indicates that A53T mutant α-syn has the highest preponderance to form 
aggregates and other α-syn mutants do not increase aggregation in this 
experimental setting. 
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transiently transfected naïve HEK293 cells, with wt, A53T, A30P and E46K mutant α-
syn and transduced the cells with 1-120 Pffs. We observed that under the conditions we 
tested, A53T mutant α-syn was the most efficient in aggregate formation, whereas A30P 
and E46K mutant did not show increased efficiency over wt α-syn, in fact they trended 
towards decreased efficiency (Figure 2-2A, B).  
Transduction without reagent is feasible, but inefficient in HEK293 A53T α-syn 
cells 
Previously, it had been shown that p-α-syn aggregate seeding through Pff 
transduction is not feasible without use of the cationic reagent Bioporter, if wt α-syn Pffs 
and wt α-syn expressing cells are used (data not shown). Because of the dramatic increase 
elicited with A53T α-syn expression and transduction with 1-120 Pffs, we wanted to test 
if with this new combination, Pff transduction would be sufficiently efficient without use 
of Bioporter reagent. When we directly added sonicated 1-120 Pffs into culture media, 
we indeed saw a number of cells forming α-syn aggregates; however, the efficiency was 
dramatically lower compared to Bioporter mediated transduction (Figure 2-3A). When 
we treated the cells with chloroquine, a lysosome inhibitor which is also used to increase 
transfection efficiency (Luthman & Magnusson, 1983), we indeed saw an increase in 
number of cells with aggregates only in no-reagent Pff transduced cells supporting that 
unless Bioporter is used, only minute amounts of endocytosed Pffs can escape lysosomal 
compartments prior to degradation (Figure 2-3A). Indeed, we observed a dramatic 
increase in Pffs retained in cells upon chloroquine treatment. 
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Figure 2-0-6: Transduction without reagent is feasible, but inefficient in HEK293 A53T α-syn 
cells  
 
 
 
 
 
 
Figure 2-3: Transduction without reagent is feasible, but inefficient in HEK293 
A53T α-syn cells (A) IF pictures showing HEK293 A53T α-syn cells transduced 
with 1-120 Pffs with or without use of Bioporter. Approximately 20% of cells 
formed small p-α-syn aggregates in no reagent Pff-td cells. With chloroquine 
treatment (+Cq), approximately 40% of cells had p-α-syn aggregates and few cells 
had larger aggregates, comparable to the ones in Bioporter Pff-td cells in size. No 
aggregates were observed in PBS transduced cells with or without chloroquine. 
(B) IB with α-syn and p-α-syn showing that without Bioporter (No BioP), 
aggregate formation is minor. Ws indicates 24h incubation with Pffs followed by 
wash with media, 1x 48h incubation with regular amount of Pffs, 2x with double 
amount of Pffs, and 1xCq 20uM Cq treatment during transduction. (C) IF pictures 
showing naïve HEK293 cells transduced with Pffs without Bioporter. 24h after 
transduction, there are very few Pffs retained in cells unless the cells are treated 
with chloroquine which dramatically enhances retention of Pffs 
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2.4 Discussion 
Here, we aimed to optimize Pff transduction system to increase its usability and 
efficacy as an α-syn aggregation model. We have found that if A53T α-syn expressing 
cells are used and they are transduced with 1-120 Pffs, the efficiency of aggregate 
formation is dramatically increased. It is likely that more positively charged 1-120 Pffs 
are internalized by the cells more readily, increasing transduction efficiency. 
Speculatively, this increased internalization is enabled by their enhanced interaction with 
the reagent, however, since they seed better also in the absence of reagent and deletion of 
negatively charged c-terminus is not expected to increase interaction with a cationic 
reagent, this possibility is less likely. Another possible explanation is that being able to 
fibrillize at an increased rate, 1-120 Pffs seed faster once they are in cytoplasm, but 
transduction with A53T α-syn Pffs was not more efficient than wt α-syn Pff (data not 
shown), which does not support this hypothesis.  
We observed that the aggregates in A53T α-syn expressing cells are not only 
more frequent, but also larger (Figure 1A), suggesting that A53T α-syn is recruited faster 
to the seeds due to its higher aggregation propensity. The evidence suggests that A30P 
mutant may form soluble oligomers which inhibit its further fibrillization (Conway et al, 
2000; Lemkau et al, 2012). It is also possible that the type of seed is important in 
fibrillization, thus A30P or E46K α-syn expression might have caused increased 
aggregate formation in the cells transduced with the same type of mutant α-syn Pffs. 
However, the focus of this study was to increase the efficiency of the system to a 
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satisfactory level and having achieved our goal with A53T α-syn/1-120 Pff combination, 
we did not test the efficiency of other combinations. 
Although the effort of rendering expensive Bioporter reagent obsolete was not 
successful, the related experiments were informative. As a proof of concept, we showed 
the Bioporter merely facilitates transduction, and if Pffs gain entry to cell by other means, 
they can also seed aggregates. Our preliminary results suggest that Pffs are degraded in 
lysosomes, thus upon chloroquine treatment, transduction efficiency is increased in no-
reagent Pff transduced cells, where the amount of retained Pffs are the limiting factor. We 
will further investigate the effect of lysosomal inhibition on Pff transduction in Chapter 3. 
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Chapter 3: Degradation of exogenous Pffs in non-neuronal 
cells 
3.1 Abstract 
Faithful models of α-syn aggregation are indispensible to study LBs and their role 
in pathogenesis. We introduced a model of α-syn aggregation in which intracellular LB-
like α-syn inclusions accumulate after cationic-lipid assisted internalization of pre-formed 
α-syn fibrils (Pffs) into α-syn-expressing cells. However, the fate of the Pffs that are 
introduced to cells was previously not well documented. Here, using cells that do not 
express α-syn, and therefore do not form LB-like aggregates, we investigated the 
mechanism through which Pffs gain access into cells. We show that Pffs are likely 
endocytosed and therefore lysosomal inhibition reduces intracellular clearance of the 
Pffs. However, we also show that only a minority of the added Pffs gain access to cells, 
while the rest remain closely attached to the cell surface. Our data indicates that, at the 
present, our-cell based model may not be ideal to study the mechanisms of Pff 
internalization or degradation due to the large amount of extracellular Pffs. However, our 
results confirm that insoluble endogenous α -syn is excellent marker for pathology, since 
LB-like aggregates are largely made of endogenous α-syn, and include only trace 
amounts of the added Pffs. We believe that the better understanding of the model we 
provided here will help interpret future results more accurately. 
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3.2 Introduction 
In our α-syn aggregation model, we introduce exogenous α-syn Pff seeds to 
cultured cells, and once these seeds gain entry to cytoplasm, they recruit endogenous α-
syn and induce formation of LB-like aggregates. We have previously showed that if these 
Pffs are directly introduced to cells, they are internalized and degraded, and this process 
can be slowed by lysosomal inhibitors (Figure 2-2, 2-3), suggesting that Pffs are 
endocytosed and go through heterophagic pathway. However, it remained unknown if 
Pffs are internalized with a similar mechanism when Bioporter reagent is used, which is 
important because this reagent vital in increasing transduction efficiency and therefore 
indispensible for our further studies in HEK293 model. Furthermore, it was also unclear 
if these Pffs can be recognized, and removed from cytoplasm by cellular degradation 
pathways. Elucidation of cellular mechanisms that can clear α-syn Pff before they seed α-
syn aggregates, may significantly contribute to the efforts of developing therapies against 
PD and related neurodegenerative diseases. 
Here, we showed that also when Bioporter is used, use of lysosomal inhibitors 
increase retention of transduced Pffs, however they do not stop their eventual elimination 
at our experimental setting. With further investigation, we discovered that with or without 
use of Bioporter, the majority of the Pffs remains extracellular, and therefore amount of 
Pffs by detected by immunoblotting is mainly constituted by extracellular Pffs. We 
concluded that due to the abundance of the extracellular Pffs, our model is not suitable to 
study degradation of internalized Pffs with our current set of tools, and the focus should 
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be on the degradation of LB-like α-syn aggregates that are almost exclusively comprised 
of endogenous α-syn.   
3.3 Results:  
Pffs are cleared from cells and this clearance is slowed by lysosomal inhibitors  
As before, we conducted our Pff degradation studies in naïve cells to refrain from 
any interference by the recruited endogenous α-syn. When naive HEK293 or HeLa cells 
(HeLa results shown, HEK293 results are comparable) are transduced with Pffs (using 
Bioporter, unless otherwise indicated), a proportion of Pffs remained associated with the 
cells 48h after transduction, and this amount was greatly increased when cells were 
treated with NH4Cl, a lysosomal inhibitor, during the course of the experiment (Figure 3-
1A). Similarly, IB showed that transduced Pffs rapidly decreased in time, and this 
decrease was slowed, but not completely inhibited by NH4Cl (Figure 3-1B,C). We also 
observed an identical effect with chloroquine, another lysosomal inhibitor (data not 
shown).  
Pffs do not significantly colocalize with early endosomes or lysosomes 
Our results thus far suggest that the Pffs are internalized by the cells through 
endocytosis. Endocytosed material first goes into early endosomes, which consequently 
mature and fuse with lysosomes (Eskelinen, 2005). Thus, we expected to see a  
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Figure 3-0-1:  Transduced Pffs are cleared from cells and this clearance is slowed by lysosomal inhibitors  
 
 
 
 
 
 
Figure 3-1: Transduced Pffs are cleared from cells and this clearance is slowed 
by lysosomal inhibitors (A) IF pictures showing Pff-td (with Bioporter) naive Hela 
cells treated with vehicle(left) or 25mM NH4Cl (right), 4 hours after transduction 
until cells are scraped (48h after transduction). The amount of retained Pffs (red) 
was significantly higher in NH4Cl treated cells. (B) IB for α-syn and GAPDH as a 
loading control. (C) Quantification of IBs from 3 independent experiments. 
Transduced Pffs were reduced with time and this reduction was slowed down by 
lysosomal inhibitor NH4Cl. [Error bars indicate SEM. Data from a minimum of 3 
independent experiments]. 
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significant subpopulation of Pff colocalize with these structures. IF using EEA1 and 
Lamp1 as markers of early endosomes and lysosomes, respectively, showed that Pffs 
only very rarely (<1%) colocalized with any of these two endosomal markers, even when 
lysosomal degradation was inhibited (Figure 3-2,data not shown). Considering that Pffs 
per se, do not colocalize with any of the cytoplasmic markers we tested thus far (p62, 
LC3, 20S proteasome; data not shown) and do not undergo phosphorylation or 
ubiquitination, this finding suggests that the majority of Pff are either inertly localized in 
cytoplasm or localized extracellularly. In addition, this observation refuted the hypothesis 
that the majority of the Pffs that do not colocalize with p-α-syn aggregates are trapped in 
endocytic compartments. 
A small proportion of added Pffs gain entry to the cells 
To investigate the possibility that the majority of the Pffs remain extracellular, we 
used confocal microscopy. Lectin-PHA was used to visualize plasma membrane. As, 
suspected, we observed that the majority of the Pffs appear to be extracellular, although 
we were also be able to detect occasional intracellular Pffs (Figure 3-3A). Similar results 
were obtained both in reagent assisted transduced cells and reagent free transduced cells 
indicating that this phenomenon is not an artifact caused by the transduction reagent (data 
not shown). Although confocal microscopy is a useful method to investigate a small 
number of cells at a time, a method which would enable us detect intracellular Pffs more 
easily, and make semi-quantitative assessments about relative amounts of intracellular 
and extracellular Pffs was needed. Therefore we devised a method, namely in-out assay, 
to easily differentiate intracellular and extracellular Pffs. The assay is a two step IF  
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Figure 3-0-2: Majority of transduced Pffs are not localized into early endosomes or lysosomes  
 
 
 
 
 
 
Figure 3-2: Majority of transduced Pffs 
are not localized into early endosomes or 
lysosomes (A-C) IF pictures showing Pff 
transduced naive HEK293 cells (A) Pffs 
only rarely colocalize with early endosomal 
marker EEA1. (B) Neither in the absence 
nor in the presence of lysosome inhibitor 
choloroquine (below, +Cq), Pffs do not 
colocalize with late endosomes/lysosomes 
decorated with Lamp1. (C) A magnified 
view of a chloroquine treated cell, showing 
lack of significant Lamp1/Pff 
colocalization.  
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Figure 3-0-3: A minute amount of Pff gain entry to cells 
  
 
 
 
 
 
Figure 3-3: A minute amount of Pff gain entry to cells (A) Confocal-IF images 
showing Pff-td naive Hela cells incubated with lectin PHΑ-L alexa 488 (green) to 
delineate plasma membrane. On the left image of a representative field, on the 
right enlarged view of the corresponding z-stack (top) and 3 more z-stacks 
obtained from different fields. Majority of the Pffs (red) appeared outside the cell, 
but closely associated with the plasma membrane, although intracellular Pffs were 
also detected (white arrows). (B) Pff in-out assay. Cells were transduced with Pffs, 
24h after transduction, they were incubated with α-syn antibody LB509 prior to 
fixation and permeabilization (indicated by “(-)‟). Following fixation and 
permeabilization (indicated by „(+)”) and incubated with another α-syn antibody 
SNL4. Controls included staining with both antibodies after fixation and 
permeabilization (bottom right) and staining with α-tubulin before and after 
fixation and permeabilization (bottom left). Intracellular Pffs that appear green 
(white arrows, arrowheads in the insets), were visible but much less common than 
extracellular Pffs that appear yellow. In both (A) and (B) nuclei stained with DAPI 
(blue). 
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procedure: the first step is to stain the cells with an α-syn antibody, while they are still 
alive and therefore their membrane is intact. 1 hour incubation to stain extracellular Pffs 
is done at 4
o
C to inhibit possible antibody endocytosis and followed by wash steps, 
fixation and the permeabilization of the cells. After permeabilization, a second α-syn 
antibody, which will not compete with the first one for Pff binding (antibodies raised 
against opposite termini are to be chosen), is used to stain both extracellular and 
intracellular Pffs, and depending on the 2
nd
ry antibodies are used at the end (typically red 
for the first and green for the second antibody), intracellular Pffs will be stained green 
only, whereas, being accessible to both antibodies, extracellular Pffs will appear yellow. 
Controls include use of both antibodies after permeabilization, use of α-tub antibody 
before and after permeabilization and switching antibody order. After confirmation of its 
feasibility in this study, this method has been used in other studies for the same purpose 
(Guo & Lee, 2011; Volpicelli-Daley et al, 2011).  
Using this new method, we confirmed that the vast majority of Pffs are 
extracellular (Figure 3-3B). Interestingly, we observed an increase in both extracellular 
and intracellular Pffs upon lysosomal inhibitor treatment, although the increase in 
intracellular Pffs appeared to be more dramatic (Figure 3-3B). In support of our previous 
results, this finding suggests that only a small fraction of Pffs are endocytosed and 
undergo lysosomal degradation, whereas the vast majority remains extracellular. 
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3.4 Discussion 
Here we showed that it is likely that Pffs can be endocytosed and degraded in 
lysosomes, however the majority of Pffs does not gain access to cells. These extracellular 
Pffs are very closely associated with cells, as rigorous washing has no effect on this 
association and extensive trypsinization (1 hour) causes only a minor reduction in 
insoluble Pffs associated with cells (Figure 3-S1). We also observed that lysosomal 
inhibitors decrease elimination of extracellular Pffs. The underlying mechanism of this 
phenomenon is not clear, however, it can be speculated that since lysosome inhibitors 
may disrupt receptor uptake and recycling (Tietze et al, 1980), they may reduce secretion 
of extracellular proteases, such as matrix metalloproteases, which could degrade Pffs. 
Regardless, we concluded that under current circumstances, our model is not suitable to 
study intracellular degradation of Pffs, thus we focused our efforts to study p-α-syn 
aggregates that are generated by recruitment of endogenous α-syn and therefore 
unequivocally intracellular. Since most of these LB-like aggregates only include minute 
amounts of extracellular seeds, Pffs can be considered as a catalyst that does not play a 
role in intracellular α-syn levels. The possible impact of extracellular Pffs, should not be 
disregarded and can be tested by use of naïve or α-syn KO cells that do not form 
aggregates. However, thus far, we did not observe any significant effect of Pff 
transduction of cells that do not form LB-like aggregates.  
In conclusion, our preliminary studies on transduced Pffs indicated that only 
minute amounts of them gain access to cytoplasm and seed aggregates, whereas the 
majority 
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Figure 0-4: Extracellular Pffs are refractory to removal by washing or trypsinization:   
 
 
 
 
 
 
Figure 3-S1: Extracellular Pffs are refractory to removal by washing or 
trypsinization IB for a-syn showing the amount of Pffs associated with naive 
HEK293 cells after various treatments. T- Triton X soluble ; S- SDS Soluble 
;Input – Sonicated Pffs; Tp- Trypsinized; Tp+BioP – Bioporter/Pff Complex 
trypsinized;  nxW – Cells washed n times with PBS before scraping; Tp- Cells are 
trypsinized, washed before scraping.  
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 remains outside without any significant effect on the cell. Therefore, we focused our 
efforts to study LB-like intracellular α-syn aggregates alone.  
3.5 Materials and Methods for Chapters 2 and 3 
Mammalian Cell Cultures 
HEK293 cells (QBiogene, CA) stably expressing wt or A53T α-syn were generated as 
previously described (Luk et al., 2009). Cells were maintained in complete media 
[DMEM (Gibco, CA), supplemented with 10% FBS, penicillin/streptomycin and L-
glutamine], and 500 µg/ml, 100 µg/ml or no G418 (Gibco, CA) was added to media for 
wt α-syn, A53T α-syn and naïve cells respectively. The day before the experiment, 
HEK293 cells were plated at a density of 60,000-75,000 cells/well on poly-D-lysine 
(PDL, 0.1 µg/ml in dH2O) and swine gelatin (0.1% w/v in dH2O) coated 12 mm 
coverslips, and 150,000-200,000 cells/well PDL coated on 12-well plates (Thermo-Fisher 
Scientific, MA).  
 Hela T-Rex (Invitrogen, CA) A53T α-syn cells were generated as per manufacturer‟s 
instructions. Briefly, A53T α-syn cDNA in the pCDNA 5TO vector (Invitrogen, CA), 
was transfected into Hela T-Rex cells and hygromycin B (Thermo-Fisher Scientific, MA) 
resistant cells that inducibly express A53T α-syn were screened by light microscopy and 
IB. Hela T-Rex A53T α-syn cells were maintained in Tet-Free complete medium 
(DMEM, supplemented with 10% Tet-Screened FBS penicillin/streptomycin, L-
glutamine) including 100 µg/ul G418 and 100 µg/ul hygromycin B. The day before the 
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experiment, Hela T-Rex cells were plated at a density of 25,000-30,000 cells/well on 
PDL coated coverslips, and 50,000-60,000 cells/well on 12-well plates. 1 µg/ml dox was 
added at the time of plating to induce α-syn expression. 
Recombinant α-syn proteins and generation of α-syn Pffs  
Recombinant wt and C-terminally truncated α-syn (remaining amino acids: 1-120) with 
and without a C-terminal myc-tag, were expressed in Escherichia coli (E. coli) and were 
purified as previously described (Giasson et al, 2001). Shortly, E. Coli BL21-RIL cells 
expressing α-syn from the pRK172 expression vector were lysed using glass mortar and 
pestle, cell lysate was cleared through heat denaturation followed by centrifugation, and 
α-syn was purified from cleared lysate by gel filtration and subsequent ion exchange 
chromatography.  
α-Syn Pffs were generated by incubating purified α-syn (5 mg/mL in PBS) at 37°C with 
constant agitation for 5 days. Electron microscopy, Thioflavin S, and protein 
sedimentation assays confirmed generation of insoluble amyloid fibrils at the end of 
incubation (Giasson et al., 2001). Generated Pffs were aliquoted and stored at −80°C.  
Pff Transduction  
Protein transduction is defined as receptor and energy independent translocation of 
proteins into cells. To deliver Pffs into cells, we decided to use a liposome mediated 
transduction method since it is more efficient and, less injurious to cells compared to 
other available methods. Pffs that are used for transduction are generated by incubation of 
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purified recombinant α-syn, at 5mg/ml concentration for 24 hours at 37
o
C on an orbital 
shaker set to 1000rpm. Obtained fibrils are diluted to 1 to 50 in PBS, sonicated 
thoroughly with a probe sonicator and incubated 10 minutes with the transduction reagent 
(BioPORTER
®
 QuikEase
™ 
: Sigmα-Aldrich, Missouri). For monomer transductions, 
100ug/ml α-syn in PBS, and for mock transductions only PBS is used. After incubation, 
Pff-Reagent mixture is mixed with warm OMEM + 1X Penn/Strep and incubated for 
another 5 minutes. Cells that were seeded to 6 or 24 well plates the day before 
transduction to reach confluence, are washed with OMEM + 1X Penn/Strep once, and 
incubated with the media containing Pff-Reagent mixture for 4-24 hours. Subsequently, 
the medium is changed to serum starvation medium (complete medium used to grow the 
specific cell line but with 0.5% instead of 10% FBS ; i.e. DMEM, 0.5% FBS, 1X 
Penn/Strep and 1X L-Glutamine for Hela cells) and the transduced cells are incubated 
overnight. After overnight serum starvation, the cells are either scraped for biochemical 
studies or trypsinized and transferred to poly-D-lysine (PDL) coated coverslips for 
immunocytochemistry (ICC).  
Drug Treatments  
 5 M ammonium chloride (NH4Cl, Thermo-Fisher Scientific, MA), 200 mM chloroquine 
(Sigmα-Aldrich, MO) and 100 mM 3-methyladenine (Sigmα-Aldrich, MO) solutions 
were prepared in dH2O immediately before each experiment. Working concentrations of 
each drug are described in the figure legends.  
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Plasmids and Transfections 
A53T a-syn pcDNA 5TO and wt a-syn pcDNA 5TO were generated using the inserts 
from available pcDNA3 a-syn constructs according to pcDNA 5TO cloning instructions 
(Invitrogen, CA). a-Syn mutant A30P and E46K had been cloned into pCDNA 3 vector 
prior to this study and used here  without any modification.HEK293 transfections were 
carried out using Fugene HD transfection reagent (Promega, WI) as per manufacturer‟s 
instructions.  
Immunofluorescence 
Cells were fixed with 4% paraformaldehyde in PBS followed by permeabilization with 
0.1% TX. After blocking with Bovine serum albumin (BSA, 3% w/v in PBS), cells were 
incubated in primary antibodies (Table 1) followed by Alexa fluor-conjugated secondary 
antibodies (Invitrogen, CA). Cells on coverslips were incubated with DAPI and mounted 
on glass slides in Fluoromount-G (SouthernBiotech, AL). For neurons, 4% w/v sucrose 
included in the fixation solution. Images were acquired using an Olympus BX 51 
microscope equipped with a digital camera DP71 and DP manager (Olympus, PA), 
except for Figures 6A and 8A, where images are acquired using Nikon Eclipse TE2000-E 
microscope equipped with CoolSnap HQ camera (Roper Scientific) and NIS Elements 
(Nikon Inc, NY). 
49 
 
Immunoblotting 
For sequential extractions, cells were scraped into 1% TX in Tris-buffered saline (TBS) 
(50 mM Tris, 150 mM NaCl, pH 7.4) and protease/phosphatase inhibitor cocktail at 4°C. 
Lysates were sonicated and centrifuged at 100,000xg for 30 min. The pellet was washed 
and suspended in 2% SDS in TBS. For total protein extractions, cells were scraped and 
sonicated directly in 2% SDS in TBS. Protein concentrations were estimated by BCA 
assay (Thermo-Fisher Scientific, MA) and equal amounts of protein were loaded on gels 
for each sample unless indicated otherwise. For sequential extractions, protein 
concentrations of TX fractions were used to calculate the volume of lysate to be loaded. 
For a given sample, TX and SDS fractions were loaded at a volume ratio of 1:2, to better 
visualize the less abundant SDS-soluble proteins. This difference in loading amounts was 
considered when TX and SDS fractions were compared in the quantification panels. 
Samples were run on 5-20% gradient SDS-Polyacrylamide gels, and proteins were 
transferred to nitrocellulose or PVDF membranes for IB. 5% fat-free milk in TBS was 
used for blocking, except for p-α-syn IB, where 7.5% BSA in TBS was used. For dot blot 
assays, samples were diluted 1:10 in TBS and loaded to Bio-Dot SF Microfiltration 
Apparatus (BioRad, CA). Proteins captured by nitrocellulose membrane were visualized 
by IB. The primary antibodies used in this study are listed in Table 1. Immunoreactivity 
was detected via chemoilluminescence by use of HRP conjugated secondary antibodies 
(Jackson Immunoresearch, PA), WesternLightning ECL substrate (Perkin Elmer, MA) 
and LAS-3000 imager (Fuji; Tokyo, Japan), or by use of IRDye secondary antibodies and 
ODY-2816 Imager (Li-Cor Biosciences, NE). 
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Quantifications, Image Processing, Statistics 
IB signals were quantified by Multi Gauge V2.3 (Fujifilm; Tokyo, Japan) or Image 
Studio V2.0 (Li-Cor Biosciences, NE). Acquired images processed with Adobe 
Photoshop CS2 (Adobe Systems Inc., CA) to facilitate visualization where needed. The 
adjustments applied equally across the entire image and to controls. All experiments were 
repeated a minimum of 3 times. The number following “±” sign indicates SEM.  
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Chapter 4: Lewy body-like α-synuclein aggregates resist 
degradation and impair macroautophagy  
4.1 Abstract 
Cytoplasmic alpha-synuclein (α-syn) aggregates, referred to as Lewy bodies 
(LBs), are pathological hallmarks of a number of neurodegenerative diseases, most 
notably Parkinson‟s disease (PD). Activation of macroautophagy is suggested to help 
degradation of certain proteinaceous inclusions, but it is unclear if this pathway is capable 
of degrading -syn aggregates. Here, we examined this issue by utilizing cellular models 
in which intracellular LB-like α-syn inclusions accumulate after internalization of pre-
formed α-syn fibrils into α-syn-expressing HEK293 cells or cultured primary neurons. 
We demonstrate that α-syn inclusions cannot be effectively degraded, even though they 
co-localize with essential components of both the autophagic and proteasomal protein 
degradation pathways. The α-syn aggregates persist even after soluble α-syn levels have 
been substantially reduced, suggesting that once formed, the α-syn inclusions are 
refractory to clearance. Importantly, we also find that α-syn aggregates impair overall 
macroautophagy by reducing autophagosome clearance, which may contribute to the 
increased cell death that is observed in aggregate-bearing cells.  
4.2 Introduction 
 Synucleinopathies are a family of neurodegenerative diseases characterized by 
cytoplasmic aggregates of the protein alpha-synuclein (α-syn), and include Parkinson‟s 
disease (PD), PD with dementia (PDD), dementia with Lewy bodies (DLB), and multiple 
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system atrophy (MSA) (Galvin et al, 2001a; Spillantini, 1999). In PD, PDD and DLB, α-
syn forms highly insoluble, fibrillar aggregates called Lewy bodies (LBs) and Lewy 
neurites (LNs) which are located in the neuronal cytoplasm or neuritic processes, 
respectively. These inclusions are rich in phosphorylated α-syn (p-α-syn), are often 
ubiquitinated (Fujiwara et al, 2002; Kuzuhara et al, 1988) and are widely distributed in 
the central nervous system (CNS), where they are associated with neuron loss 
(Wakabayashi et al, 2007). Moreover, α-syn mutations and α-syn gene 
duplication/triplication are linked to familial forms of PD (Kruger et al, 1998; 
Polymeropoulos et al, 1997; Singleton et al, 2003; Zarranz et al, 2004). Collectively, 
these findings implicate α-syn aggregates in the onset and progression of disease. Thus, it 
is important to gain a better understanding of whether -syn inclusions can be effectively 
degraded by cells, and whether these aggregates might negatively affect key cellular 
pathways. 
 The removal of protein aggregates, as well as misfolded, damaged and regulated 
proteins, occurs via two main degradation pathways; the ubiquitin- proteasome system 
(UPS) and the autophagy-lysosomal pathway (ALP) (reviewed by(Rubinsztein, 2006). 
Macroautophagy, a prominent constituent of the ALP, is responsible for removal of both 
soluble and aggregated proteins, as well as damaged organelles, via their sequestration 
into double-membrane vesicles called autophagosomes, followed by their degradation by 
catalytic enzymes after autophagosome/lysosome fusion (Mortimore et al, 1996; Seglen 
et al, 1996). Macroautophagy (hereafter, autophagy) has been implicated in bulk 
degradation of pathologic aggregates, such as the poly-glutamine-expanded huntingtin 
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inclusions observed in Huntington‟s disease (Ravikumar et al, 2002). ALP is a vital 
cellular process and impairment of the ALP can lead to neurodegeneration, as 
demonstrated in animal models that are deficient in genes coding for autophagy proteins 
in neuronal tissue (Hara et al, 2006; Komatsu et al, 2006), and in human 
neurodegenerative lysosomal storage diseases (Futerman & van Meer, 2004; Nixon et al, 
2008).  
 Both the UPS and ALP have been implicated in the degradation of soluble, non-
aggregated α-syn (Cuervo et al, 2004; Ebrahimi-Fakhari et al, 2011; Webb et al, 2003), 
and autophagy is believed to be the pathway responsible for degradation of soluble 
oligomeric α-syn species (Ebrahimi-Fakhari et al, 2011). However, it is not clear if 
autophagy plays a role in the clearance of LB-like α-syn aggregates, as a heretofore lack 
of in vitro models that faithfully recapitulate α-syn aggregation has made it difficult to 
address this question. Unlike many aggregate-prone proteins, simple overexpression of α-
syn does not lead readily to the formation of insoluble inclusions. Therefore, additional 
manipulations have been used to generate α-syn aggregates in cultured cells, including 
co-expression of proteins such as synphillin-1 (Engelender et al, 1999) and exposure to 
proteolytic inhibitors, oxidative stress, or nitrative insult (Lee et al, 2002; McLean et al, 
2001; Paxinou et al, 2001), which likely directly or indirectly affect protein degradation 
pathways. However, the -syn aggregates formed in these various cellular paradigms 
typically fail to exhibit several important characteristics of LBs, including ubiquitination 
and the presence of insoluble phosphorylated α-syn. To better model LB-like inclusions 
in cultured cells, we recently developed models of α-syn aggregation in which the 
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introduction of pre-formed α-syn fibrils (Pffs) into cells, including primary neurons from 
wildtype (wt) non-transgenic mice, results in recruitment of endogenously expressed α-
syn and formation of insoluble α-syn aggregates resembling LBs and LNs (Luk et al, 
2009; Volpicelli-Daley et al, 2011). The ability to generate α-syn aggregates efficiently, 
without using any treatment that directly perturbs protein degradative function, provides 
model systems to investigate the possible interplay between autophagy and α-syn 
aggregates. 
 Here, we have investigated whether Pff-seeded, LB-like α-syn aggregates can 
be removed by autophagy. We observed that pathologic α-syn aggregates cannot be 
effectively eliminated and that they cause a partial impairment of autophagosome 
clearance that could contribute to the decreased viability observed in cells harboring -
syn deposits. Thus, our findings provide novel insights into the effects of α-syn 
aggregates on cellular metabolism and viability, and may have implications regarding 
potential therapeutic strategies for synucleinopathies.  
 
4.3 Results 
Insoluble α-syn aggregates interact with protein degradation machinery. 
The HEK293 model of LB-like -syn inclusions, in which -syn-expressing cells 
are transduced with -syn Pffs to induce aggregate formation (Luk et al, 2009), provides 
a cellular system to evaluate whether α-syn aggregates undergo proteolytic degradation. 
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Utilizing this model, we first assessed by immunofluorescence (IF) the localizations of 
several proteins involved in the ALP (Figure 4-1). These include p62, an adaptor protein 
that recruits autophagy machinery to protein aggregates (Bjorkoy et al, 2006); LC3, a 
protein specifically localized to autophagosome membranes when in its lipidated form 
(LC3-II) (Kabeya et al, 2000); and Lamp1, a marker of lysosomes and 
autophagolysosomes (Fukuda, 1991). In control PBS-transduced (PBS-Td) cells without 
α-syn aggregates, p62 and LC3 staining was faint and punctuate, and spread across the 
cytoplasm (Figure 4-1). In contrast, in Pff-transduced (Pff-td) cells bearing α-syn 
aggregates, p62 and LC3 staining was largely redistributed (Figure 4-1), such that the 
majority of the p-α-syn aggregates showed co-localization with accumulations of these 
proteins (97.4% ± 1.3% for p62 and 77.8% ± 5.5% for LC3). Autophagy substrates 
should progressively localize to autophagolysosomes, which are the product of 
autophagosome-lysosome fusion and where substrates are normally degraded by 
lysosomal proteases (Xie & Klionsky, 2007). In contrast with p62 and LC3, the 
lysosome/autophagolysosome marker Lamp1 did not show appreciable colocalization 
with α-syn aggregates (10.2% ± 6.0%; Figure 4-1). These data suggest that the α-syn 
inclusions are associated with the early autophagy machinery, but may not be delivered to 
autophagolysosomes.  
In addition to co-localization with p62 and LC3, the -syn aggregates in Pff-td 
cells were also observed to be associated with the 20S proteasome (Figure 4-1). It was 
previously demonstrated that most α-syn inclusions in the HEK293 model are  
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Figure 4-0-1: Co-localization of protein degradation pathway components with α-syn aggregates  
 
 
 
 
 
Figure 4-1: Co-localization of protein degradation pathway components with α-
syn aggregates . 
Immunofluorescence (IF) images of HEK293 α-syn cells 24 h after Pff 
transduction, stained with p-α-syn antibody (red), DAPI (blue), or antibodies to 
p62, LC3, Lamp1, and 20S Proteasome (green). Dispersed and punctate 
cytoplasmic staining of p62 and LC3 was observed in PBS-td cells. In Pff-td cells, 
p-α-syn aggregates showed strong co-localization with p62 and LC3. Similarly, 
there was diffuse staining of the 20S proteasome in the PBS-td cells, whereas Pff-
td cells had cytoplasmic 20S proteasome staining that largely co-localized with α-
syn aggregates. In contrast, Lamp1-positive vesicles were observed in both PBS-td 
and PFf-td cells, and these did not typically co-localize with p-α-syn aggregates. 
[Scale bars = 20µm].  
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ubiquitinated and that they co-localize with the molecular chaperone, Hsp70 (Luk et al, 
2009). These findings suggest that proteasome components, as well as those from the 
ALP, are recruited to the -syn aggregates, likely in an attempt to degrade the inclusions. 
Alternatively, these proteasome and autophagy constituents may interact aberrantly with 
aggregates, an event that could affect their function. 
Insoluble α-syn aggregates are not degraded by autophagy and their clearance is 
severely impaired. 
To elucidate if α-syn aggregates are degraded by autophagy, we evaluated 
whether autophagy inhibition or activation affected the levels of p-α-syn. HEK293 cells 
stably expressing α-syn (HEK293 α-syn) were treated for 24 h with either an inhibitor of 
autophagosome formation, 3-methyadenine (3-MA) (Kabeya et al, 2000; Seglen & 
Bohley, 1992), or an activator of autophagy, rapamycin (Rap). Drug treatment was 
initiated 4 h after PBS or Pff transduction, a time when only minimal α-syn aggregation 
has occurred. Immunoblotting revealed that neither 3-MA nor Rap caused a significant 
change in p--syn levels, although rapamycin treatment trended towards an increase of p-
α-syn (Figure 4-2A,B). Examination of parallel cultures 4 h after drug addition, a time 
which allows for the detection of cell-associated myc-tagged Pffs, revealed that neither 
drug affected cellular Pff levels (Figure 4-S1A). The effectiveness of the drug treatments 
is seen in an LC3 immunoblot, with the expected decrease and increase of LC3-II 
formation after 3-MA and Rap treatment, respectively (Figure 4-S1A). Likewise, there 
were corresponding drug-induced changes in the abundance of LC3-positive puncta as 
visualized by IF (Figure 4-S1B). We also noted that there was a significant decrease in  
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Figure 4-0-2: Autophagy does not degrade α-syn aggregates and clearance of aggregated α-syn is severely impaired  
 
 
 
 
Figure 4-2: Autophagy does not degrade α-syn aggregates and clearance of 
aggregated α-syn is severely impaired. After 4 h Pff transduction, HEK293 α-syn 
cells were treated with the 3-MA (10 mM) or rapamycin (Rap, 0.2 µM) in 
starvation media for 24 h. (A) Representative IB of p-α-syn and α-tubulin (α-tub), 
and (B) quantification of IBs from 3 independent experiments. “0h” refers to cells 
that were harvested prior to drug treatment, and “(-)” refers to vehicle-treated cells. 
(C,D,E) Hela T-Rex cells that express α-syn under the control of a doxycyline 
(dox)-inducible promoter were induced with dox for 16 h. After removal of dox, 
cells were transduced for 4 h and then incubated in dox-free starvation media until 
they were sequentially extracted. (C) Representative IB for endogenous α-syn, p-
α-syn and α-tub. Equal volumes of cell extract were loaded. (D) Quantification of 
IBs from 3 independent experiments. The α-syn levels in TX fractions at 0 h after 
transduction were used to normalize α-syn levels at other time points. (E) Graph 
showing total (TX+SDS) α-syn levels. In PBS-td cells, α-syn was rapidly cleared 
from cells, whereas in Pff-td cells, no net α-syn reduction was observed. Error bars 
±SEM. One-way ANOVA with Tukey‟s post-hoc analysis was used to test for 
statistically significant differences between treatments. NS and ** indicates p>0.05 
and p<0.01, respectively. Scale bars = 20 µm. 
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Figure 0-3: Modulation of autophagy and α-syn aggregates  
 
 
 
 
Figure 4-S1: Modulation of autophagy and α-syn aggregates. (A) 4 h after Pff 
transduction, cells were treated with vehicle (-),10 mM 3-MA, or 0.2 µM rapamycin (Rap), 
for an additional 4h until they were harvested in 2% SDS. Representative IB showing 
decreased and increased LC3-II levels with 3-MA and Rap, respectively. The levels of myc-
tagged Pffs were not significantly affected. (B) IF images of Pff-td cells treated with vehicle 
(-), 3-MA, or Rapamycin. Abundance of LC3 (red) puncta were greatly reduced with 3-MA 
treatment and increased with Rap treatment. The abundance of p-α-syn (green) aggregates 
was not significantly affected by the treatments, however, they did not colocalize with LC3 
in 3-MA treated cells, where LC3 is mostly cytoplasmic. (C,D) 4 h after Pff transduction, 
HEK293 α-syn cells were maintained in nutrient rich media for 20 h, followed by rapamycin 
treatment for 72 h in the absence or presence of 15 µM Cq in nutrient–rich conditions. (C) 
IB of p-α-syn, p62, LC3 and the loading control, α-tub. (D) Quantification of p-α-syn levels 
in IBs from 3 independent experiments, with data normalized to the mean p-α-syn level from 
vehicle-treated, Pff-td cells. (E,F) HEK293 α-syn cells were transfected with the dominant 
negative autophagy inhibitor, mutant ATG4BC74A-strawberry, or with empty vector (-). 
Cells were transduced with Pff for 24 h, treated with 30 µM Cq for an additional 24 h, and 
then harvested 72 h after transfection. (E) IB of p-α-syn, p62, LC3 and the loading control, 
α-tub. (F) Quantification of p-α-syn levels from 3 independent experiments, with data 
normalized to the mean p-α-syn level from empty vector transfected Pff-td cells. [Error bars 
±SEM. Student‟s paired t test was used to test for statistically significant differences. NS and 
* indicate p>0.05 and p<0.05 respectively. Scale bar = 20µm]. 
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the amount of LC3 that was recruited to the aggregates when the cells were treated with 
3-MA (Figure 4-S1B), confirming that the α-syn inclusions normally associate with 
autophagosome-conjugated LC3-II and not with cytoplasmic forms of LC3 that are 
increased after 3-MA treatment.  
Although Rap treatment of the HEK293 -syn cells resulted in an enhancement of 
autophagy (Figure S1A,B) Rap-induced autophagy activation may have been attenuated 
because of prior activation of autophagy caused by serum deprivation during transduction 
(Mortimore & Poso, 1987). To eliminate this possibility, HEK293 -syn cells were 
treated with Rap for 72 h under nutrient-rich conditions, and Rap did not significantly 
affect p-α-syn levels in the Pff-td cells, although the observed increase of LC3-II 
confirmed activation of autophagy (Figure S1C). Similarly, p-α-syn levels were not 
affected by treatment with the lysosome inhibitor, chloroquine (Cq) (Figure S1C,D), even 
though this drug clearly affected LC3-II clearance. Importantly, inhibition of autophagy 
by expression of a dominant negative ATG4B mutant, prevents lipidation of LC3 to LC3-
II, thereby inhibiting autophagosome closure and autophagy (Fujita et al, 2008)) did not 
lead to an elevation of p--syn (Figure S1E,F), although it resulted in significantly 
decreased total and LC3-I normalized LC3-II levels in ATG4B transfected cells 
(2.34±0.30 vs 0.63±0.05 in Pff-td mock and ATG4B transfected cells, respectively. 
p<0.01). These data thus confirm that seeded α-syn aggregates in HEK293 cells are not 
appreciably degraded by autophagy. 
As the 20S proteasome subunit was found associated with p--syn aggregates 
(Figure 1), we also queried whether inhibition of proteasome function would affect the 
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levels of -syn aggregates. Addition of the proteasome inhibitor, clasto-lactacystin-betα-
lactone (c-lac) did not increase Triton-X insoluble p-α-syn or -syn in the Pff-td cells 
(Figure 4-S2Α-C), although c-lac treatment led to a significant increase in high molecular 
weight ubiquitinated proteins (HMW Ub; Figure 4-S2A,D), thereby demonstrating 
inhibition of proteasomal degradation. These results suggest that α-syn aggregates are not 
cleared effectively by either autophagic or proteasomal pathways. To further confirm this 
conclusion, another α-syn expression model was utilized in which α-syn is under the 
control of a doxycyline (dox)-inducible promoter. After growth for 16 h in dox-
containing medium to induce α-syn expression, the cells were transduced with -syn Pffs 
and subsequently grown for varying lengths of time in dox-free medium to suppress α-
syn synthesis. The cells underwent sequential extractions and samples were analyzed by 
immunoblotting, using a C-terminal α-syn antibody that recognizes endogenous -syn 
and not the C-terminal truncated 1-120myc -syn Pffs. In PBS-td cells, Triton-X100 
(TX) soluble α-syn was rapidly degraded, with the amount of α-syn remaining 72 h after 
dox removal being 29.9±5.1% of the amount observed immediately (0 h) after 
transduction (Figure 4-2C,D). In Pff-td cells, TX-soluble α-syn decreased at a faster rate 
over time, concomitant with a progressive increase in TX-insoluble/SDS-soluble α-syn 
levels (Figure 4-2C,D). However, no net degradation of total α-syn was detected in the 
Pff-td cells 72 h after dox removal, while there was a substantial decrease of total α-syn 
in the PBS-treated cells (Figure 4-2D,E). Taken together, these data indicate that α-syn 
aggregates are not effectively degraded by any cellular mechanism in the time-frame of 
this study, including but not limited to the UPS and ALP. 
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Figure 0-4: The UPS does not effectively clear α-syn aggregates.  
 
 
 
 
 
 
 
 
 
Figure 4-S2: The UPS does not effectively clear α-syn aggregates. HEK293 α-syn 
cells were transduced with Pffs or PBS and 24 h later were treated with the 
proteasome inhibitor clasto-lactacystin-beta-lactone (c-lac, 10 µM) for an additional 
24 h. The cells were sequentially extracted in 1% TX, followed by 2% SDS. (A) 
Representative IBs for p-α-syn, α-syn, ubiquitin, and the loading control, GAPDH, 
with (B,C,D) quantification of IBs from 3 independent experiments. C-lac treatment 
significantly increased high molecular weight ubiquitinated (HMW ub) protein 
levels. However, it did not increase insoluble p-α-syn or α-syn, demonstrating that 
proteasome activity does not reduce α-syn pathology. Pff transduction caused an 
increase in HMW ub protein levels, which may indicate that their degradation is 
impaired in transduced cells. [Error bars ±SEM. In (B) and (C), Student‟s t test, and 
in (D) one-way ANOVA with Tukey‟s post-hoc analysis used to test for statistically 
significant differences. NS, *, ** and *** indicate p>0.05, p<0.05, p<0.01 and 
p<0.001, respectively].  
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Typical autophagy substrates accumulate in α-syn aggregate-bearing cells. 
As previously noted, LC3-II and p62 are autophagy substrates whose levels are 
routinely used to monitor autophagic function (Klionsky et al, 2007; Mizushima et al, 
2010; Rubinsztein et al, 2009). Interestingly, both of these proteins accumulated in Pff-td 
HEK293 α-syn cells (Figure 4-S1C,E), but not in Pff-td naïve HEK293 cells that do not 
express α-syn and therefore do not form α-syn aggregates (Figure 4-3A,B). Additionally, 
the levels of TX-insoluble high molecular weight (HMW) ubiquitinated proteins, which 
are typically degraded by autophagy (Bartlett et al, 2011; Pankiv et al, 2007), were 
significantly increased in Pff-td HEK293 α-syn cells in the absence or presence of 
proteasome inhibition (Figure 4-S2A,D), but not in Pff-td naïve HEK293 cells (Figure 4-
3C,D). These data suggest an impairment of autophagy in aggregate-bearing cells. 
α-Syn aggregates also interact with autophagy and proteasome components in 
neurons but are resistant to degradation. 
To determine if α-syn aggregates in primary wild-type (wt) neurons are also 
resistant to degradation, we utilized a recently developed neuronal model of α-syn 
pathology where endogenous mouse α-syn readily aggregates to form LB-like α-syn 
inclusions when transduced with α-syn Pffs (Volpicelli-Daley et al, 2011). The α-syn 
aggregates in neurons, like those in HEK293 α-syn cells, co-localized with ubiquitin 
(Volpicelli-Daley et al, 2011), p62 and the 20S proteasome, but not with Lamp1 
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Figure 5 Typical autophagy substrates accumulate in α-syn aggregate-bearing cells.   
 
 
 
 
Figure 4-3: Typical autophagy substrates accumulate in α-syn aggregate-bearing 
cells. (A,B) 48 h after Pff transduction, α-syn and naïve HEK293 cells were 
harvested and proteins were extracted in SDS. (A) Representative IB for p-α-syn, 
p62, LC3 and the loading control, α-tub. (B) Quantification of IBs from 3 
independent experiments, with protein levels in Pff-td cells expressed as a 
percentage of the corresponding PBS control level. (C,D) 48 h after transduction, α-
syn and naïve HEK293 cells were extracted in TX and then SDS. (C) Representative 
IB for HMW ubiquitin (ub), α-syn, with α-tub as a loading control. (D) 
Quantification of IBs from 3 independent experiments, with Pff-td cell levels 
expressed as a percentage of the corresponding PBS-td cell levels. Insoluble Ub 
protein levels did not increase in Pff-td naïve HEK293 cells. Error bars ±SEM. 
Student‟s paired t test was used to test for statistically significant differences. NS and 
* indicate p>0.05, and p<0.05, respectively. 
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(Figure 4-4A). Live imaging of LC3-mRuby transfected neurons revealed that LC3-
positive vesicles co-localized with α-syn aggregates and accumulated in Pff-td neuronal 
processes, and immuno-EM with p-α-syn antibodies demonstrated that these aggregates 
can be found in close association with vesicle-like structures, but not inside these vesicles 
(Figure 4B). These data suggest that α-syn inclusions associate with autophagy 
components in neurons, but are not efficiently delivered to autophagolysosomes for 
degradation.  
To further confirm that neuronal -syn aggregates, like those in HEK293 -syn 
cells, are not effectively cleared by autophagy, Pffs were introduced into neurons that had 
been cultured in vitro for 10 days (DIV10). At DIV13, before significant amounts of α-
syn aggregates were generated (Volpicelli-Daley et al, 2011), the Pff-td neurons were 
treated for 48 h with 3-MA to inhibit autophagy, or with starvation media to activate 
autophagy (Young et al, 2009). As expected, 3-MA caused accumulation of the 
autophagy substrate p62 in the TX-soluble fraction, whereas starvation slightly reduced 
its levels (Figure 4C). However, neither treatment significantly affected p-α-syn levels 
(Figure 4C,D), suggesting that α-syn inclusions in neurons are not significantly degraded 
by autophagy during the time–frame of these studies.  
To further examine clearance of α-syn aggregates in neurons, α-syn expression 
was reduced in PBS or Pff-td wt neurons by transfection of an anti-α-syn siRNA. Despite 
a significant reduction in endogenous -syn expression after siRNA treatment (77%±5%; 
compare –siRNA and +siRNA at 10d in Figure 4E), insoluble α-syn progressively 
accumulated in the siRNΑ-treated Pff-td neurons during the course of experiment  
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Figure 4-0-6: α-Syn aggregates interact with protein degradation pathway components but cannot be effectively 
degraded in neurons  
 
 
 
Figure 4-4: α-Syn 
aggregates interact with 
protein degradation 
pathway components but 
cannot be effectively 
degraded in neurons. At 5 
days in vitro (DIV), 
primary hippocampal 
neurons were transduced 
with human wt α-syn Pffs, 
and analyzed at 19 DIV. 
(A) IF using indicated 
antibodies, demonstrating 
that neuronal α-syn 
aggregates co-localized 
with p62 and 20S 
proteasome but not with 
Lamp1 (B) Top; images of 
neurons transfected with 
LC3-mRuby and α-syn-
GFP, showing 
accumulation of LC3 
puncta that co-localized 
with p-α-syn aggregates in 
Pff-td neuronal processes. 
Bottom; Immuno-EM, 
showing nano-gold-labeled 
p-α-syn aggregates at 
50,000X magnification, 
with proximal autophagic 
vesicle-like 
structures.(C,D) At DIV10, 
neurons were transduced 
with wt α-syn Pffs, and at 
DIV13 they were starved or 
treated with 10 mM 3-MA. 
Pff-td cells in one well 
were harvested at DIV13 to 
monitor pre-treatment 
levels of p-α-syn (denoted 
as “0h”). The rest were 
harvested at DIV15. (C) IB 
for indicated antibodies 
(Tuj-1, neuron specific 
βIII-tubulin). (D) 
Quantification of IBs. (E,F) 
At DIV5, neurons were 
transduced with PBS or wt 
α-syn Pffs and after 24 h 
were transfected with anti-
α-syn siRNA, or vehicle. 
Cells were harvested 10, 14 
and 17 days after 
vesicle-like structures.(C,D) At DIV10, neurons were transduced with wt α-syn Pffs, and at 
DIV13 they were starved or treated with 10 mM 3-MA. Pff-td cells in one well were 
harvested at DIV13 to monitor pre-treatment levels of p-α-syn (denoted as “0h”). The rest 
were harvested at DIV15. (C) IB for indicated antibodies (Tuj-1, neuron specific βIII-tubulin). 
(D) Quantification of IBs. (E,F) At DIV5, neurons were transduced with PBS or wt α-syn Pffs 
and after 24 h were transfected with anti-α-syn siRNA, or vehicle. Cells were harvested 10, 14 
and 17 days after transduction. (-) siRNA denotes vehicle transfected PBS-td cells harvested 
10 days after transduction. (E) Representative IB for mouse specific endogenous α-syn (m-α-
syn). (F) Quantification of IBs from 3 independent experiments. Error bars ±SEM. One-way 
ANOVA with Tukey‟s post-hoc analysis used. NS indicates p>0.05. Scale bar=20 µm (A), 
500 nm (B). Images used in panel (B) are provided by Laura Volpicelli-Daley and Anna 
Stieber. 
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(Figure 4-4E,F). Thus, even a low level of α-syn expression was enough to sustain the 
growth of α-syn aggregates, suggesting that α-syn aggregates are not cleared from 
neurons at a significant rate.  
Finally, Pff-td wt neurons, but not Pff-td neurons from α-syn knock-out (KO) 
mice, showed increased p62, LC3-II and TX-insoluble HMW ubiquitin protein levels 
(Figure 4-5Α-D), demonstrating that accumulation of these proteins are not caused 
simply by the addition of Pffs, but rather by the m-α-syn inclusions that are seeded by 
Pffs. Moreover, these data suggest that α-syn aggregates impair autophagy in neurons, as 
was observed in HEK293 cells.  
Autophagy function is impaired in -syn aggregate-bearing cells. 
To further substantiate that α-syn aggregates impair autophagy function, we 
examined the degradation of the established autophagy substrate, YFP-tagged huntingtin 
exon 1 fragment with 72 glutamine repeats (Htt Q72), which forms highly insoluble 
aggregates that are degraded by autophagy (Pollitt et al, 2003; Ravikumar et al, 2002). 
Htt Q72 and p-α-syn did not associate with each other when examined by IF in Pff-td 
cells (Figure 4-6A). However, insoluble Htt Q72 levels were greatly increased in Pff-td 
cells compared to PBS-td cells (Figure 4-6B,C). The difference in insoluble Htt Q72 
levels between the PBS-td and Pff-td cells was largely negated when autophagy was 
inhibited with 3-MA, and was enhanced when autophagy was further activated with Rap 
(Figure 4-6B,C). This indicates that the increase in Htt Q72 levels in Pff-td cells is due to 
an impairment in autophagic function that cannot be overcome by enhancement of 
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Figure 4-0-7: Canonical autophagy substrates accumulate in neurons with α-syn accumulations.  
 
 
 
 
 
 
Figure 4-5: Canonical autophagy substrates accumulate in neurons with α-syn 
accumulations. Primary hippocampal neurons from wt or α-syn knock-out (KO) 
mouse embryos were cultured in nutrient-rich neuronal media. At DIV5, neurons 
were transduced with human α-syn Pffs or PBS, and neurons were harvested for IB 
at DIV19. (A,C) Representative IB for p-α-syn, m-α-syn, ub, p62, LC3 and α-tub. 
(B,D) The effect of Pff transduction on levels of immunoblotted proteins in wt and 
α-syn KO neurons. Proteins levels are shown as a percentage of the values of PBS-td 
cells. TX-insoluble HMW ub proteins, p62, LC3-II and m-α-syn levels were 
significantly increased in Pff-treated neurons, suggesting that removal of these 
proteins was impaired. No change was observed in Pff-td α-syn KO neurons. Error 
bars ±SEM. Student‟s paired t test was used to test for statistically significant 
differences. No asterisk, *, ** and *** indicate p>0.05, p<0.05, p<0.01 and p<0.001, 
respectively. Scale bar = 20 µm. 
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Figure 4-0-8: Autophagy function is reduced in α-syn aggregate bearing cells.  
 
 
Figure 4-6: Autophagy function is reduced in α-syn aggregate bearing cells. (A,B,C) 48 h 
after PBS or Pff transduction, HEK293 α-syn cells were transfected with YFP-tagged Htt 
Q72. 20 h after transfection, the cells were treated with 10 mM 3-MA, 0.2 µM Rap or vehicle 
(-) for 24 h. (A) Diffuse, soluble (left) or aggregated (right) Htt Q72 (green) did not co-
localize with p-α-syn (red) aggregates. (B) Representative IBs for p-α-syn and GFP 
(recognizes YFP tag of Htt), as well as Ponceau S total protein staining. The Htt Q72 within 
TX-insoluble cellular fractions was visualized by dot immunoblot. (C) Quantification of dot 
blots from 4 independent experiments. Ratio of insoluble Htt Q72 levels in Pff-td and PBS-td 
cells for each treatment condition is indicated below the graph. (D,E) 48 h after transduction, 
HEK293 α-syn or naïve HEK293 cells were transfected with YFP-tagged Htt Q72, and 48 h 
after transfection harvested for IB. (D) Representative IBs for GFP and Ponceau S total 
protein staining. The Htt Q72 within TX-insoluble cellular fractions was visualized by dot 
IBs. (E) Quantification of dot blots from 4 independent experiments, shown as ratio of 
insoluble Htt Q72 levels of Pff-td and PBS-td cells. Error bars ±SEM. Statistical significance 
was determined by (B,E) Student‟s paired t test and (D) one-way ANOVA with Tukey‟s post-
hoc analysis. NS, *, ** and *** indicate p>0.05, p<0.05, p<0.01 and p<0.001, respectively. 
Scale bars = 20 µm. 
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 autophagosome formation. That the amount of insoluble Htt Q72 was substantially 
increased in Pff-td cells upon 3-MA addition reveals there was not a complete cessation 
of autophagy-mediated degradation of Htt Q72 in the α-syn aggregate-bearing cells in the 
absence of 3-MA. Although there was a modest increase of Htt Q72 clearance in the Rap-
treated PBS-td cells, the Rap effect was likely muted in both the PBS-td and Pff-td cells 
because autophagy was already activated due to maintenance under starvation conditions 
after transduction. As expected, p-α-syn levels remained essentially unaffected by the 3-
MA and Rap (Figure 6B). Likewise, Pff transduction did not increase Htt Q72 levels in 
naïve HEK293 cells that do not form α-syn aggregates (Figure 6D, E), demonstrating that 
α-syn Pffs do not by themselves impair autophagy, nor do they seed Htt Q72 aggregates. 
Together, these and previous data indicate that autophagy function is 
compromised in α-syn aggregate-bearing cells, as evidenced by the accumulation of 
canonical autophagy substrates and the partial inhibition of Htt Q72 degradation.  
Autophagosome clearance is impaired in -syn aggregate-bearing cells. 
As the autophagy pathway consists of multiple steps, including autophagosome 
formation, maturation, and subsequent clearance of autophagosomes, we investigated 
whether α-syn aggregates specifically interfere with any of these steps. Our data suggest 
that autophagosome formation is not prevented, as demonstrated by the large number of 
LC3-II-positive autophagosomes that are associated with -syn aggregates, and the 
increased LC3-II levels observed in Pff-td cells (Figure 4-1, Figure 4-2C, Figure 4-
S1A,C,E and Figure 4-3A,B). However, LC3-II levels could also be elevated as the result 
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of an elevation in autophagosome synthesis, rather than or in addition to an inhibition of 
autophagosome clearance. To distinguish between these possibilities, we utilized a LC3-
II turnover assay (Mizushima et al, 2010). PBS-td and Pff-td HEK293 α-syn cells were 
treated for 4 h with a high concentration of chloroquine (100 M) to inhibit all lysosomal 
degradation. This treatment abolished the differences in LC3-II levels between PBS-td 
and Pff-td cells (Figure 4-7A,B), and such a result is typically observed when there is an 
impairment of autophagosome clearance (Mizushima et al, 2010; Rubinsztein et al, 
2009). This was further confirmed when PBS-td and Pff-td cells were simultaneously 
treated with Rap and Cq for 4 h, to induce accumulation of a large pool of autophagic 
vesicles. After removal of both drugs, LC3-II levels rapidly decreased in the PBS-td cells, 
so that more than half of the LC3-II was cleared in 24 h and nearly all LC3-II was 
degraded by 48-72 h (Figure 4-7C,D). Remarkably, there was no net clearance of LC3-II 
in Pff-td cells after 24 h, and LC3-II levels remained significantly higher than the 
corresponding level observed in PBS-td cells at each later time-point (Figure 4-7C,D). It 
should be noted that the residual effects of Cq likely caused a transient slowing in the 
elimination of LC3-II in both PBS and Pff-td cells (Zetser et al, 2004). Nonetheless, these 
data suggest that α-syn aggregates do not inhibit formation of autophagosomes, but rather 
impair autophagosome clearance.  
Lysosome function appears normal in -syn aggregate-bearing cells. 
The absence of Lamp1 co-localization with α-syn aggregates (Figure 4-1) 
suggests that the resistance of α-syn deposits to degradation and the impairment of 
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Figure 4-0-9: Autophagosome clearance is impaired in α-syn aggregate-bearing cells.  
 
 
 
Figure 4-7: Autophagosome clearance is impaired in α-syn aggregate-bearing cells. 
(A,B) HEK293 α-syn cells were incubated in nutrient-rich media for 4 h after Pff 
transduction and the cells were treated with 100 µM of the lysosome inhibitor 
chloroquine (Cq) 48 h after transduction. After 4 h of incubation with Cq, the cells 
were lysed in SDS buffer. (A) Representative IB for p-α-syn, LC3 and the loading 
control, α-tub. (B) Quantification from 4 independent experiments. Pff-td and PBS-td 
cells showed comparable LC3-II levels upon complete inhibition of autophagosome 
clearance by Cq, suggesting that autophagosome clearance is impaired. (C,D) 
HEK293 α-syn cells were incubated in nutrient-rich media 4 h after Pff transduction 
and cells were treated with 0.2 µM rapamycin and 100 µM Cq 48 h after transduction. 
This “pulse” generated a large pool of autophagosomes in both Pff-td and PBS-td 
cells. After 4 h, the drugs were removed, and cells were harvested 0, 24, 48 and 72 h 
later. As a control, a set of cells was treated only with vehicle and were harvested 72 h 
after treatment. (C) Representative IB for LC3 and α-tub. (D) Quantification of 3 
independent experiments. Error bars ±SEM. In (B) and (D) Student‟s t test was used 
to test for statistically significant differences. NS, *, and ** indicate p>0.05, p<0.05, 
and p<0.01, respectively. 
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 autophagosome clearance may be caused by a defect in autophagosome maturation, 
rather than by an impairment of lysosomal degradation. Nevertheless, lysosomal defects 
could contribute to decreased autophagosome clearance by inhibiting lysosome-
autophagosome fusion (Kawai et al, 2007). To investigate whether α-syn aggregates 
affect Lamp1-positive lysosomes, we conducted IF analyses in PBS-td and Pff-td 
HEK293 cells. Although lysosomes appeared primarily as abundant fine puncta in PBS-
td cells, they were less abundant and enlarged in Pff-td cells. The frequency of giant 
lysosomes (>2.5 µm in diameter), which were rarely observed in PBS-td cells, was 
significantly increased in Pff-td cells (Figure 4-8A). No such change in lysosome 
morphology was observed in Pff-td naïve HEK293 cells (Figure 4-S3A), demonstrating 
that formation of giant lysosomes was caused by the formation of LB-like α-syn 
aggregates, rather than simply Pff treatment. Giant lysosomes could also be readily 
observed in PBS-td cells after treatment with lysosomal protease inhibitors (Figure 4-8A, 
B). Notably, lysosomal inhibition did not result in the accumulation of p-α-syn 
aggregates in giant lysosomes within Pff-td cells, or increased Lamp1/p-α-syn 
colocalization (7.0%±2.6% with inhibitor versus 10.2%± 6.0% without inhibitor).This 
suggests that the lysosomal dilation observed in Pff-td cells was not due to the 
sequestration and subsequent degradation of α-syn aggregates in lysosomal compartments 
(Figure 4-8A).  
Lysosomal enlargement may indicate possible lysosomal dysfunction, which 
could lead to impaired autophagosome clearance. Therefore, we asked if the giant 
lysosomes in Pff-td cells are functional. The lysosomal processing of a fluorogenic  
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Figure 4-0-10: Lysosome morphology, but not catalytic function, is affected in Pff-td cells.  
 
Figure 4-8: Lysosome morphology, but not catalytic function, is affected in Pff-td cells. 
(A)24 h after Pff transduction, cells were treated for 24 h with a lysosomal protease inhibitor 
cocktail (Lysosome Inh.) or vehicle (-). The IF images shows examples of giant (>2.5µm in 
diameter) Lamp1-positive (green) vesicles in Pff-td cells (arrowheads). Quantification of giant 
Lamp1 vesicles, shown as number of vesicles per 100 nuclei (blue), is shown on the right. Pff-
td cells harbored significantly more giant lysosomes than PBS-td cells. Lysosomal inhibitor 
treatment eliminated this difference. Colocalization between p-α-syn (red) and Lamp1 (green) 
was not observed in the absence or presence of inhibitor treatment. (B) The fluorogenic 
lysosomal substrate, Magic Red MR-(RR)2, is cleaved by the lysosomal protease Cathepsin-B 
(Cath-B) to yield a fluorescent product. Both normal lysosomes and the giant lysosomes in 
Pff-td cells converted the fluorogenic substrate, suggesting that lysosomal function was 
unaffected by the α-syn aggregates. Treatment with lysosomal inhibitors (top-right) 
diminished lysosomal fluorescence, confirming dependence of Magic Red MR-(RR)2 
cleavage on proper lysosome function. (C) A representative IB (n=3) is shown which reveals 
similar EGF-induced EGFR degradation by lysosomes in PBS-td and Pff-td cells 30 min and 
120 min after addition of EGF. EGFR was not substantially degraded in PBS-td or Pff-td cells 
in the absence of EGF (EGF -). Cq treatment inhibited EGFR degradation, confirming that the 
reduction of EGFR after EGF treatment was dependent on lysosome function. Statistical 
significance was determined with Student‟s t test. NS, ** indicate p>0.05, and p<0.01, 
respectively Scale bars = 20 µm. 
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Cathepsin-B substrate, Magic Red-RR(2), as well as the lysosomal degradation of the 
epidermal growth factor (EGF) receptor after addition of EGF, were assessed in Pff-td 
cells.  Notably, lysosome function was maintained in these cells, as both processing of 
the Magic Red substrate (Figure 8B) and degradation of the EGFR (Figure 8C) was 
observed. The integrity of lysosomes in Pff-td cells was also supported by experiments 
which demonstrated that the enlarged lysosomes had a normal pH (as monitored by 
Lysosensor; Figure 4-S3C), and that the lysosomal protease, Cathepsin D, could be 
properly processed from its Procathepsin D precursor (Figure S3D).  
As lysosomal function in Pff-td cells appeared to be normal, we asked if 
autophagy impairment in α-syn aggregate-bearing cells might result from a defect in 
autophagosome maturation. This could be due to reduced autophagosome/lysosome 
fusion, or to a reduced number of fully matured autophagosomes that are available for 
lysosomal fusion. A step in autophagosome maturation that precedes lysosomal fusion is 
amphisome formation, during which autophagosomes fuse with multivesicular bodies 
(MVBs) (Eskelinen, 2005). Utilizing the MVB marker CD63 (Escola et al, 1998), the 
localizations of CD63, LC3, Lamp1 and p-α-syn were compared in PBS-td and Pff-td 
cells. PBS-td cells showed light and diffuse staining for LC3 and CD63, with some co-
localization of these markers (Figure 4-9A). However, inhibition of lysosome function 
caused accumulation of LC3 vesicles which largely co-localized with both CD63 and 
Lamp1, demonstrating that these vesicles matured to amphisomes and 
autophagolysosomes before their clearance was blocked by the lysosomal inhibitors 
(Figure 9A, B). LC3-positive vesicles accumulated and co-localized with p--syn in Pff- 
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Figure 0-11: Effect of Pff-td on Lysosomes  
 
Figure 4-S3: Effect of Pff-td on Lysosomes. (A) 24 h after Pff transduction, naive HEK293 
cells were treated for 24 h with a lysosomal inhibitor cocktail (Lys. Inh.) or vehicle (-).The IF 
images show that the PBS-td and Pff-td cells show similar lysosome morphology, with few 
giant lysosomes. Lysosomal inhibitor treatment resulted in an increase of giant (>2.5µm in 
diameter) Lamp1 (green)-positive vesicles, as indicated with arrowheads. Quantification of 
giant Lamp1 vesicles, shown as number of vesicles per 100 nuclei (blue), is shown on the 
right. (B) WT neurons were examined by IF 14 days after PBS or Pff transduction. Lamp1 
(green) vesicles appeared as abundant, fine puncta in PBS-td cells, whereas in Pff-td cells they 
were typically enlarged and clustered with p-α-syn (red) aggregates. (C) HEK293 α-syn cells 
were incubated with lysosensor 48 h after PBS or Pff transduction to visualize lysosomal pH. 
Giant lysosomes in the Pff-td cells were brightly stained with lysosensor, indicating that they 
retained an acidic pH. Treatment with lysosomal inhibitors (top-right) eliminated the punctate 
lysosomal staining, demonstrating the pH dependence of the fluorescent dye. (D) HEK293 
cells were treated with Cq or vehicle 48 h after PBS or Pff transduction. 24 h after treatment, 
cells were lysed and underwent IB analysis to determine the extent of processing of the 
lysosomal protease Cathepsin-D (Cath-D), which is cleaved from Procathepsin-D (Procath-D) 
in functional, acidic lysosomes (Hasilik et al., 1982). [n>=2 for all experiments. NS indicates 
p>0.05. Scale bars = 20 µm]. 
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Figure 4-0-12: Autophagosomes associated with p-α-syn aggregates are impaired in maturation  
 
 
Figure 9A: Autophagosomes associated with p-α-syn aggregates are impaired in 
maturation. 24 h after PBS or Pff transduction, HEK293 α-syn cells were treated for 24 h 
with a lysosomal inhibitor cocktail (Lysosome Inh.) or vehicle (-) before they were fixed for 
IF. (A) IF images showing CD63 (red), LC3 (green), p-α-syn (blue, white dotted outline), and 
nuclei (denoted as “Nu”). There were few LC3 and CD63 puncta in PBS-td cells, and these 
did not co-localize in the absence of lysosomal inhibitor. However, LC3 and CD63 co-
localization was observed in the PBS-td cells when the clearance of autophagic vesicles was 
prevented by lysosomal inhibitor treatment. In Pff-td cells, LC3 vesicles that accumulate with 
p-α-syn aggregates were not generally co-localized with CD63 vesicles. Inhibition of 
lysosomes resulted in some overlap of CD63 and LC3, but CD63 did not localize to LC3 
vesicles associated with p-α-syn. Although they did not co-localize with the p-α-syn 
aggregates, CD63 vesicles in Pff-td cells appeared to be larger and more variable in size 
compared to those in PBS-td cells[n>=3 for all experiments. Scale bars = 20 µm]. 
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Figure 9B: Autophagosomes associated with p-α-syn aggregates are impaired in 
maturation. 24 h after PBS or Pff transduction, HEK293 α-syn cells were treated for 24 h 
with a lysosomal inhibitor cocktail (Lysosome Inh.) or vehicle (-) before they were fixed 
for IF. (B) IF images showing Lamp1 (red), LC3 (green), p-α-syn (blue, white dotted 
outline), and nuclei (denoted as “Nu”). Lamp1 co-localized with LC3 in PBS-td cells 
treated with lysosomal inhibitor, and in cells without α-syn aggregates in Pff-td cells after 
addition of lysosome inhibitor. However, Lamp1 was largely excluded from LC3 vesicles 
that overlapped with α-syn aggregates in Pff-td cells in the absence or presence of 
lysosome inhibitor. [n>=3 for all experiments. Scale bars = 20 µm]. 
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td cells in the absence of lysosomal inhibition, but there was little overlap of LC3 with 
CD63 (Figure 4-9A) or Lamp1 (Figure 4-9B) at the sites of p--syn aggregates. As with 
PBS-td cells, inhibition of lysosomal function in Pff-td cells resulted in an increase of 
CD63 and Lamp1 co-localization with LC3, with the exception that CD63 and Lamp1 
staining was generally not observed in LC3-positive p--syn aggregates (Figure 4-9A, 
B). Although there was minimal localization of CD63 with p-α-syn aggregates in Pff-td 
cells, either in the absence or presence of lysosomal inhibition (11.8%±2.6% and 
6.7%±4.1%, respectively), the observed CD63-containing MVBs were not associated 
with -syn aggregates. However, they appeared to be enlarged, as was seen with Lamp1-
positive vesicles (Figure 4-8A and Figure 4-9A). These data support the interpretation 
that the LC3-positive autophagosomes that associate with α-syn aggregates do not mature 
to amphisomes. Moreover, the enlarged LC3/CD63-positive amphisomes that do form in 
Pff-td cells and which are not associated with -syn aggregates may have altered 
properties that could provide an explanation for the partial impairment of autophagic 
function observed in the cells harboring -syn inclusions.  
Autophagy activation enhances cellular toxicity in -syn aggregate-bearing cells. 
Previous studies have shown that activation of autophagy may attenuate 
cytotoxicity of aggregate-prone proteins that are degraded by autophagy (Sarkar et al, 
2009; Young et al, 2009). However, our data suggest that the resistance of α-syn 
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Figure 0-13: Treatments that activate autophagy increase the toxicity of α-syn aggregates.:   
 
 
 Figure 4-S4: Treatments that activate autophagy increase the toxicity of α-syn 
aggregates. (A) A lactate dehydrogenase (LDH) release assay was performed to 
monitor cell death in naïve HEK293 cells or HEK293 cells that express α-syn. Only 
Pff transduced HEK293 α-syn cells (α-syn Pff), showed significantly increased LDH 
release. (B) PBS- or Pff transduced HEK293 α-syn cells were maintained in nutrient-
rich complete media (comp), treated with rapamycin or maintained in starvation media 
after transduction, until a tetrazolium-based viability assay was carried out. Both 
starvation and rapamycin treatment significantly reduced viability in transduced cells 
(C,D) Pff- or PBS-td wt neurons were starved, or treated with rapamycin  and the 
LDH release assay (C) and the viability assay (D) were performed. Starvation 
significantly increased cell death and decreased viability in neurons and rapamycin, 
trended towards the same pattern. [Error bars ±SEM. In (A) and (B), one-way 
ANOVA with Tukey‟s post-hoc analysis used to test for statistically significant 
differences. In (C) and (D), student‟s paired t test was used to test for statistically 
significant differences. NS, *, ** and *** indicate p>0.05, p<0.05, p<0.01 and 
p<0.001 respectively] 
 
A 
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aggregates to autophagy is not the result of a defect in autophagy initiation, but rather a 
problem of autophagasome maturation. Thus, a strategy of autophagy activation may not 
be productive in cells containing -syn inclusions, and in fact the cell death that is 
observed in both aggregate-bearing HEK293 cells and neurons (Figure 4-S4A 
and(Volpicelli-Daley et al, 2011) is exacerbated upon activation of autophagy with 
rapamycin or serum-starvation (Figure 4-S4B-D). Although it is possible that the increase 
in toxicity observed with these treatments results from cellular mechanisms other than 
autophagy, these data are consistent with the notion that increased autophagosome 
generation can be detrimental in cells when autophagosome clearance is impaired 
(Boland et al, 2008; Wong & Cuervo, 2010; Zhang et al, 2011). 
4.4 Discussion 
 Utilizing recently developed cellular models of Pff-seeded α-syn aggregation, we 
have demonstrated that LB-like inclusions are resistant to degradation despite their 
interaction with ALP and UPS components. These aggregates persist even when soluble 
α-syn levels are substantially reduced, indicating that once seeding occurs, pathologic α-
syn aggregates are refractory to clearance from the cells. Interestingly, overall autophagic 
clearance is impaired in the α-syn aggregate-bearing cells, which may be a factor 
contributing to the observed reduction in cellular viability. Importantly, alterations of 
autophagy were observed in both non-neuronal cells and in primary cultured neurons 
harboring α-syn aggregates. Indeed, the neuronal Pff transduction model of α-syn 
aggregation is unique in that α-syn aggregates can be formed with very high efficiency in 
the absence of α-syn overexpression or toxic insults that may perturb autophagy or 
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proteasome function. Moreover, our cellular models of α-syn seeding with recruitment of 
endogenous α-syn to yield LB-like aggregates may replicate key aspects of 
synucleinopathies, as several recent lines of evidence suggest that the spreading of 
amyloid protein pathology, such as seen with α-syn in PD, may result from the neuronal 
release and uptake of extracellular α-syn seeds (Angot et al, 2010; Brundin et al, 2010; 
Luk et al, 2012; Soto, 2012).  
Previous studies revealed that LBs in PD co-localize with UPS and ALP 
components such as ubiquitin, 20S proteasome, p62 and LC3 (Higashi et al, 2011; Ii et al, 
1997; Kuzuhara et al, 1988; Zatloukal et al, 2002). However, it was unclear whether these 
associations resulted in degradation of LBs. Although LB-like inclusions co-localized 
with UPS and ALP components in our cell models, such interactions did not to lead to 
degradation of α-syn aggregates. A similar recruitment of ALP components has also been 
observed with other aggregated proteins that are resistant to autophagic degradation 
(Wong et al, 2008). The failure to degrade α-syn aggregates cannot be explained by a 
complete inhibition of autophagy, as Htt Q72 appeared to be degraded in aggregate-
bearing cells, albeit at a significantly reduced rate, suggesting that α-syn aggregates are 
selectively resistant to degradation. As with a number of other protein aggregates subject 
to autophagy, Htt Q72 aggregates occur as “aggresomes”, which are believed to be 
actively generated by cells to sequester misfolded proteins within the cytoplasm 
(Kaganovich et al, 2008; Kopito, 2000; Markossian & Kurganov, 2004). However, Pff-
seeded α-syn aggregates do not show robust co-localization with aggresomal markers 
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such as vimentin (Kawaguchi et al, 2003; Luk et al, 2009), suggesting that they are a 
distinct type of inclusion that is resistant to degradation. 
The demonstration that cells harboring aggregated α-syn have partial impairment 
of  autophagy complements prior studies which showed that soluble α-syn species may 
reduce autophagic activity (Cuervo et al, 2004; Martinez-Vicente et al, 2008; Winslow et 
al, 2010). The α-syn inclusions appear to impair autophagy by reducing autophagosome 
clearance. This disruption of autophagy may contribute to the cellular toxicity seen in the 
aggregate-bearing cells, and we observed further cell death upon activation of autophagy. 
Autophagosome clearance defects have been previously suggested in neurodegenerative 
diseases. For instance, the abnormal accumulation of autophagosomes in AD brain tissue 
is thought to be caused by impaired autophagosome clearance (Boland et al, 2008), and 
LC3-II levels are elevated in PD brain tissues with abundant LB pathology (Higashi et al, 
2011). An impairment of autophagosome clearance is likely to be detrimental, as removal 
of both unwanted, damaged proteins and defective organelles such as mitochondria 
(Elmore et al, 2001; Novak et al, 2010), is vital for cells. Therefore, impairment of 
autophagy may lead to cell death through several different mechanisms, including 
oxidative stress, which is strongly implicated in PD pathogenesis (Jenner & Olanow, 
1996; Zhang et al, 2000). (Jenner & Olanow, 1996; Zhang et al, 2000). Indeed, several 
proteins that are implicated in PD pathogenesis, including ATP13A2, LRRK2 and Pink-
1, may also affect autophagy function (Gomez-Suaga et al, 2012; Michiorri et al, 2010; 
Usenovic et al, 2012), suggesting that autophagic dysfunction may be a primary cause of 
cell death in PD. 
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The LC3-positive autophagic vesicles that accumulate with α-syn aggregates were 
not decorated with markers of amphisomes and autophagolysosomes, indicating that 
autophagosome maturation is likely impaired prior to amphisome formation. The 
resistance of α-syn aggregates to degradation may be caused by an inability of aggregate-
associated autophagosomes to migrate within the cell, and/or an inability of MVBs to 
fuse with the autophagosomes. Alternatively, it is possible that α-syn aggregates interfere 
with the ability of autophagosomes to mature, such that the LC3-positive structures that 
accumulate in aggregate-bearing cells are incomplete or abnormal. In addition to the -
syn inclusions being refractory to autophagic degradation, it appears that there is a more 
general impairment of autophagy in aggregate-containing cells. Interestingly, the Pff-td 
cells show an enlargement of both CD63- and Lamp1-positive vesicular bodies, although 
lysosome function seems to be unaltered. These changes may suggest that the α-syn 
aggregates have an effect on vesicle-related cellular processes, including autophagy. 
Indeed, α-syn aggregates perturb endosomal trafficking in yeast by interacting with rab 
proteins (Gitler et al, 2008; Soper et al, 2011). 
In conclusion, we have demonstrated that seeded α-syn aggregates are resistant to 
degradation and impair autophagosome clearance. These findings have bearing on 
therapeutic strategies in PD and related synucleinopathies, as prior studies have indicated 
that autophagy activation via rapamycin treatment may attenuate disease phenotype in 
certain in vivo models of PD (reviewed by (Bove et al, 2011). Although the models used 
in these studies may provide important insights, they typically rely on oxidative insults or 
proteasome inhibitors to achieve the desired phenotype, and these treatments could 
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increase the cellular dependence on autophagic removal of damaged mitochondria and 
unwanted proteins (Lee et al, 2012; Ogata et al, 2006). In addition, neurons in these 
models lack the insoluble, LB-like α-syn aggregates that are observed in our cellular 
models and in synucleinopathies. Our studies suggest that activation of autophagy may 
not be effective once α-syn aggregates form, which is likely to occur before clinical 
symptoms manifest. On the contrary, autophagy activation may be harmful to -syn 
aggregate-bearing cells because of the impaired autophagosome clearance. However, it is 
possible that alternative therapeutic approaches, such as restoration of normal autophagic 
flux (Lee & Gao, 2009; Li et al, 2011), may reduce the ALP impairment caused by the α-
syn aggregates and be effective in enhancing the survival of affected cells. Further studies 
will determine if these approaches can reduce neurodegeneration in PD and related 
synucleinopathies. 
4.5 Materials and Methods 
Mammalian and Primary Neuronal Cell Cultures 
HEK293 cells (QBiogene, CA) stably expressing wt or A53T α-syn were 
generated as previously described (Luk et al., 2009). Cells were maintained in complete 
media [DMEM (Gibco, CA), supplemented with 10% FBS, penicillin/streptomycin and 
L-glutamine], and 500 µg/ml, 100 µg/ml or no G418 (Gibco, CA) was added to media for 
wt α-syn, A53T α-syn and naïve cells respectively. The day before the experiment, 
HEK293 cells were plated at a density of 60,000-75,000 cells/well on poly-D-lysine 
(PDL, 0.1 µg/ml in dH2O) and swine gelatin (0.1% w/v in dH2O) coated 12 mm 
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coverslips, and 150,000-200,000 cells/well PDL coated on 12-well plates (Thermo-Fisher 
Scientific, MA).  
 Hela T-Rex (Invitrogen, CA) A53T α-syn cells were generated as per manufacturer‟s 
instructions. Briefly, A53T α-syn cDNA in the pCDNA 5TO vector (Invitrogen, CA), 
was transfected into Hela T-Rex cells and hygromycin B (Thermo-Fisher Scientific, MA) 
resistant cells that inducibly express A53T α-syn were screened by light microscopy and 
IB. Hela T-Rex A53T α-syn cells were maintained in Tet-Free complete medium 
(DMEM, supplemented with 10% Tet-Screened FBS penicillin/streptomycin, L-
glutamine) including 100 µg/ul G418 and 100 µg/ul hygromycin B. The day before the 
experiment, Hela T-Rex cells were plated at a density of 25,000-30,000 cells/well on 
PDL coated coverslips, and 50,000-60,000 cells/well on 12-well plates. 1 µg/ml dox was 
added at the time of plating to induce α-syn expression. 
Primary mouse hippocampal neurons were cultured and maintained as previously 
described (Volpicelli-Daley et al, 2011). Briefly, hippocampi dissected from E16-E18 
C57BL/6 or CD-1 mouse brains (Charles River, MA) and α-syn KO mice (Abeliovich et 
al, 2000), were treated with papain and DNAse, and dissociated neurons were plated in 
plating media [Neurobasal Media (Gibco, CA), supplemented with 10% FBS, 
penicillin/streptomycin, Glutamax, B27] on PDL (0.1 mg/mL, in 0.1 M borate buffer 
pH8.4) coated coverslips at a density of 60,000-100,000 cells/well or PDL coated 12-well 
plates at 400,000-600,000 cells/well. Plating media was changed to neuronal media 
(Neurobasal Media, supplemented with penicillin/streptomycin, Glutamax, B27) 2-18 h 
after plating. 
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Recombinant α-syn proteins and generation of α-syn Pffs  
Recombinant wt and C-terminally truncated α-syn (remaining amino acids: 1-120) 
with and without a C-terminal myc-tag, were expressed in Escherichia coli (E. coli) and 
were purified as previously described (Giasson et al, 2001). Shortly, E. Coli BL21-RIL 
cells expressing α-syn from the pRK172 expression vector were lysed using glass mortar 
and pestle, cell lysate was cleared through heat denaturation followed by centrifugation, 
and α-syn was purified from cleared lysate by gel filtration and subsequent ion exchange 
chromatography.  
α-Syn Pffs were generated by incubating purified α-syn (5 mg/mL in PBS) at 
37°C with constant agitation for 5 days. Electron microscopy, Thioflavin S, and protein 
sedimentation assays confirmed generation of insoluble amyloid fibrils at the end of 
incubation (Giasson et al., 2001). Generated Pffs were aliquoted and stored at −80°C.  
Pff Transduction 
Unless indicated otherwise, HEK293 or Hela T-Rex cells expressing A53T α-syn, 
and α-syn Pffs generated from C-terminally myc tagged and truncated α-syn (1-120) were 
used for non-neuronal Pff transductions. By using this combination of cells and Pffs, a 
4.7-fold increase in percentage of cells bearing aggregates (78.5% ±0.7% vs 
16.7%±3.5%, 48h after transduction) was elicited compared to wt α-syn cells wt α-syn 
Pffs combination. Cells were washed with Opti-MEM (Gibco, CA), before transduction. 
For dox-induced Hela cells, cells were rinsed 3 times with Opti-MEM for 5 min each to 
completely remove dox. 0.8 µg of sonicated α-syn Pffs in 80 µl dPBS (Cellgro, MA) 
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were added to a tube of protein transduction reagent Bioporter (Sigmα-Aldrich, MO), and 
incubated 10 min at room temperature. After incubation, 420 µl of Opti-MEM was added 
to the reagent tube and one tube of diluted reagent/Pff complex was used to transduce 4 
wells on a 12-well plate or 8 coverslips. After 4 h, Opti-MEM with reagent/Pff complex 
was removed and cells were maintained in low-serum starvation media (DMEM, 0.25% 
FBS supplemented with penicillin/streptomycin, L-glutamine) unless indicated otherwise. 
In neurons, wt α-syn Pffs were diluted in PBS at 100 µg/mL, sonicated 65 times, and 
diluted in neuronal media. For coverslips 0.5 µg and for 12-well plate wells 5 µg of α-syn 
Pffs were added directly to culture media at 5 or 10 DIV. Neuronal media of transduced 
cells was not removed earlier than 3 days after transduction. Where indicated, neurons 
were starved in starvation medium (DMEM, penicillin/streptomycin) to activate 
autophagy (Young et al, 2009). 
Drug Treatments  
2.5 mg/ml Rapamycin in DMSO (Sigma-Aldrich, MO) was stored at -20
o
C, and 
was diluted 1:10 in DMSO before each experiment. Lysosome inhibitor cocktail 
components, Leupeptin hemisulphate, Pepstatin A, and E46d (all from Sigma-Aldrich, 
MO) were prepared at: 20 mM in dH2O, 2 mM in DMSO and 10 mM in DMSO, 
respectively, and kept at -20
o
C. 5 M ammonium chloride (NH4Cl, Thermo-Fisher 
Scientific, MA), 200 mM chloroquine (Sigma-Aldrich, MO) and 100 mM 3-
methyladenine (Sigma-Aldrich, MO) solutions were prepared in dH2O immediately 
before each experiment. Working concentrations of each drug are described in the figure 
legends.  
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Plasmids and Transfections 
The pYFPN1-Htt-Q72 plasmid was a generous gift of Dr. Robert Baloh. HEK293 
transfections were carried out using Fugene HD transfection reagent (Promega, WI) as 
per manufacturer‟s instructions. Neurons were transfected with LC3-RFP and α-syn-GFP 
plasmids using Lipofectamine 2000 (Invitrogen, CA) according to manufacturer‟s 
instructions. Transfection was done at DIV5 and neurons were transduced at DIV6. Live 
images are acquired using Nikon Eclipse TE2000-E microscope equipped with CoolSnap 
HQ camera (Roper Scientific) and NIS Elements (Nikon Inc, NY). For siRNA 
transfections, Lipofectamine siRNAMAX (Invitrogen, CA) was used according to 
manufacturer‟s instructions. The sequence of the anti-mouse-α-syn siRNA duplex was: 
5‟-GCAUGAGACUAUGCACCU-3‟ and 5‟-UAUUUAUAGGUGCAUAGU-3‟. 
Transfection was carried out at DIV6, 1 day after transduction. 
Lysosomal function assays 
Magic Red Cathepsin MR-(RR)2 (Immunochemistry Technologies, MN) was 
used to monitor Cathepsin-B activity in HEK293 cells, according to manufacturer‟s 
intstructions. Briefly, 48h after transduction, cells were incubated with the Magic Red 
reagent for 15 mins, washed in imaging buffer (10mM HEPES, 136mM NaCl, 2,5mM 
KCl, 2mM CaCl2, 1.3mM MgCl2, 10mM glucose) and the fluorescent signal generated by 
proteolytic activity was observed using a fluorescent microscope. For EGFR degradation 
assay, 48h after transduction, HEK293 cells were incubated with 200nm/ml murine EGF 
(Peprotech, NJ) or BSA for 30, and 120 minutes. As a positive control, a set of EGF 
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treated wells were pre-incubated with 100uM chloroquine for 1h. At the end of 
incubations, cells are harvested in 2% SDS lysis buffer for immunoblotting. 
Immunofluorescence 
Cells were fixed with 4% paraformaldehyde in PBS followed by permeabilization 
with 0.1% TX. For LC3 and Lamp1 staining, digitonin (100 µg/ml) used for 
permeabilization. For 20S proteasome staining, cells were permeabilized during fixation 
with 1% TX to reduce nuclear staining. After blocking with Bovine serum albumin 
(BSA, 3% w/v in PBS), cells were incubated in primary antibodies (Table 1) followed by 
Alexa fluor-conjugated secondary antibodies (Invitrogen, CA). Cells on coverslips were 
incubated with DAPI and mounted on glass slides in Fluoromount-G (SouthernBiotech, 
AL). For neurons, 4% w/v sucrose included in the fixation solution. Images were 
acquired using an Olympus BX 51 microscope equipped with a digital camera DP71 and 
DP manager (Olympus, PA), except for Figures 6A and 8A, where images are acquired 
using Nikon Eclipse TE2000-E microscope equipped with CoolSnap HQ camera (Roper 
Scientific) and NIS Elements (Nikon Inc, NY). 
Immunoblotting 
For sequential extractions, cells were scraped into 1% TX in Tris-buffered saline 
(TBS) (50 mM Tris, 150 mM NaCl, pH 7.4) and protease/phosphatase inhibitor cocktail 
at 4°C. Lysates were sonicated and centrifuged at 100,000xg for 30 min. The pellet was 
washed and suspended in 2% SDS in TBS. For total protein extractions, cells were 
scraped and sonicated directly in 2% SDS in TBS. Protein concentrations were estimated 
91 
 
by BCA assay (Thermo-Fisher Scientific, MA) and equal amounts of protein were loaded 
on gels for each sample unless indicated otherwise. For sequential extractions, protein 
concentrations of TX fractions were used to calculate the volume of lysate to be loaded. 
For a given sample, TX and SDS fractions were loaded at a volume ratio of 1:2, to better 
visualize the less abundant SDS-soluble proteins. This difference in loading amounts was 
considered when TX and SDS fractions were compared in the quantification panels. 
Samples were run on 5-20% gradient SDS-Polyacrylamide gels, and proteins were 
transferred to nitrocellulose or PVDF membranes for IB. 5% fat-free milk in TBS was 
used for blocking, except for p-α-syn IB, where 7.5% BSA in TBS was used. For dot blot 
assays, samples were diluted 1:10 in TBS and loaded to Bio-Dot SF Microfiltration 
Apparatus (BioRad, CA). Proteins captured by nitrocellulose membrane were visualized 
by IB. The primary antibodies used in this study are listed in Table 1. Immunoreactivity 
was detected via chemoilluminescence by use of HRP conjugated secondary antibodies 
(Jackson Immunoresearch, PA), WesternLightning ECL substrate (Perkin Elmer, MA) 
and LAS-3000 imager (Fuji; Tokyo, Japan), or by use of IRDye secondary antibodies and 
ODY-2816 Imager (Li-Cor Biosciences, NE). 
Immuno Electron Microscopy 
 Immuno-EM were conducted as described before (Volpicelli-Daley et al, 2011). 
Shortly, 14 days after Pff-treatment, neurons were fixed in periodate-lysine-
paraformaldehyde and permeabilized with 0.05% saponin in PBS with 2% fish gelatin 
and 0.05% thimerosal followed by incubation in p-α-syn antibody. Neurons were then 
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incubated with goat anti-mouse IgG coupled to nanogold (Nanoprobes, Yaphank, NY). 
The nanogold labeled neurons were postfixed and gold toned with 0.05% gold chloride. 
Quantifications, Image Processing, Statistics 
Colocalization of p-α-syn aggregates and inclusions of Pdp related proteins was 
quantified by manual counting using Image J (NIH, USA). Inclusion was defined as a 
cytoplasmic region with clearly increased IF signal compared to surrounding cytoplasmic 
areas of the same cell. IF pictures from 3 or 4 independent experiments were used for 
quantification, a minimum of 100 p-α-syn aggregates was counted for each condition. IB 
signals were quantified by Multi Gauge V2.3 (Fujifilm; Tokyo, Japan) or Image Studio 
V2.0 (Li-Cor Biosciences, NE). Acquired images processed with Adobe Photoshop CS2 
(Adobe Systems Inc., CA) to facilitate visualization where needed. The adjustments 
applied equally across the entire image and to controls. All experiments were repeated a 
minimum of 3 times. The number following “±” sign indicates SEM. Statistical analyses 
used for each experiment were indicated in figure legends, all analyses were carried out 
using Graphpad Prism 4 (Graphpad Software Inc, CA).  
4.6 Supplementary Materials and Methods 
Drug Treatments, Plasmids and Transfections  
C-lac (Calbiochem; Darmstadt, Germany) was dissolved in DMSO at 10 mM, and 
stored at -20
o
C. pmStrawberry-Atg4BC74A (Addgene plasmid 21076) (Fujita et al, 2008) 
was generated by Dr. Tamotsu Yoshimori and deposited to Addgene. Transfection was 
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carried out using Fugene HD transfection reagent (Promega, WI) as per manufacturer‟s 
instructions. Lamp1-RFP plasmid (Addgene plasmid 1817)(Sherer et al, 2003) was 
generated by Dr. Walther Mothes and deposited to addgene with a comment indicating 
that Lamp1 sequence in this plasmid contains two point mutations which are not 
important for function. Neurons were transfected with Lamp1-RFP plasmid using 
Lipofectamine 2000 (Invitrogen, CA) according to manufacturer‟s instructions. 
Transfection was done at DIV5 and neurons were transduced at DIV6. Live images are 
acquired using Nikon Eclipse TE2000-E microscope equipped with CoolSnap HQ 
camera (Roper Scientific) and NIS Elements (Nikon Inc, NY). 
Toxicity Assays  
CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, WI) was used to 
monitor LDH release as an indicator of cytotoxicity and the CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (Promega, WI) was used to monitor MTS tetrazolium 
reduction to cell estimate viability, according to manufacturer‟s instructions. HEK293 
cells were treated for 48 h with rapamycin 48 h after transduction. Complete media 
(“Comp”) indicates that transduced cells were incubated in nutrient-rich media, starting 
from 4 h after transduction, for 92 h. For neurons, 7 days after transduction, cells were 
starved in DMEM or treated with rapamycin for 7 days. For viability assays, HEK293 
cells and neurons are incubated with MTS tetrazolium substrate for 1 h, and 4 h 
respectively. Results are shown as ratios of Pff and PBS-td cells, that received the same 
treatment. 
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Table 1: Antibodies used in this study 
 
Antigen Antibody Application Dilution Source 
20S Proteasome PW 8155 IF 1:2000 Biomol 
alpha-tubulin T9026 IB 1:5000 Sigma-Aldrich 
α-syn (human) Syn211 IB 1:2000 (Bruening et al, 2000) 
α-syn (mouse) mSyn-1 IB 1:500 (Vopicelli-Daley et al., 2011) 
CD-63 CD-63 IF 1:500 (Abache et al, 2007) 
GFP sc-9996 IB 1:500 Santa Cruz 
Lamp1 (human) H4A3 IF,IB 1:1000, 1:1000 BD biosciences 
Lamp1 (mouse) 1D4B IF 1:500 Developmental Studies 
Hybridoma 
LC3 PM036 IF, IB 1:2000, 1:500 MBL 
myc 9E10 IF 1:2000 DHSB 
p62 (human) 610832 IF, IB 1:2000, 1:1000 BD Transduction 
p62 (mouse) 2C11 IF, IB 1:1000, 1:1000 Abnova 
p-α-syn  81a IF, IB 1:8000, 1:1000 (Waxman & Giasson, 2008) 
p-α-syn  p-α-syn 6.2 IF 1:1000 (Luk et al, 2012) 
Tuj-1 MMS-435P IB 1:5000 Covance 
Ubiquitin Ub1B4 IB, IF 1:1000, 1:1000 (Sampathu et al, 2006) 
Figure 0-14: Antibodies used in this study:   
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Chapter 5: General Conclusions and Discussion  
 
In this study, we investigated the interplay between LB-like α-syn aggregates and 
Pdps, using a novel cell based model of Parkinson‟s disease. This study is unique in the 
sense that not only the α-syn aggregates investigated are very similar to LBs and LNs 
observed in brains of those who suffer from synucleinopathies, but also the method used 
to generate them may accurately recapitulate their formation in vivo. Furthermore, unlike 
common methods used to induce formation of α-syn inclusions, Pff-seeding does not alter 
Pdp function, thereby rendering this model very suitable to study the interplay between α-
syn aggregates and Pdps. Thus, we believe that our findings will help improve our 
understanding of the role of LBs in pathogenesis. In the rest of this chapter, we will 
further elaborate the discussion on our findings and speculate about the possible 
mechanism of autophagy impairment, the differences between LB-like seeded aggregates 
and non-fibrillar α-syn inclusions and possible therapeutic implications of our findings. 
 
5.1 Possible mechanisms of α-syn aggregate mediated impairment of 
autophagy  
The autophagic vesicles that accumulate with the aggregates only contained early 
autophagosome markers, which may indicate that autophagosome maturation is impaired. 
It is possible that this impairment is directly caused by diminished autophagosome 
transport due to sequestration of the autophagosomes by α-syn aggregates. Another 
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possibility is that the LB-like aggregates affect development of the phagophore, so that 
the autophagosomes that surround the aggregates are abnormal or incomplete. It is 
possible that the affinity of α-syn to membranes may interfere with this membrane based 
process. However, abnormal lysosome/late endosome morphology we observed suggests 
that the aggregates may also have an indirect effect on autophagy, or vesicle trafficking 
in general. Indeed, it was previously shown that golgi is dispersed in Pff-td HEK293 cells 
(Luk et al, 2009), and α-syn aggregates perturb endosomal trafficking in yeast by 
interacting with rab proteins (Gitler et al, 2008; Soper et al, 2011). It is also possible that 
the synaptic deficits observed in Pff-td neurons (Volpicelli-Daley et al, 2011) are 
contributed by defects in vesicle trafficking. Interestingly, our findings are remarkably 
similar to the effects of PI(3,5)P2 deficiency, which is implicated in human 
neurodegenerative diseases, particularly ALS (Chow et al, 2009; Chow et al, 2007). 
Reduction of this signaling lipid causes impaired autophagosome clearance (Ferguson et 
al, 2009), formation of giant lysosomes/late endosomes but does not significantly affect 
lysosomal proteolytic function such as EGFR degradation (Ikonomov et al, 2003). Thus, 
α-syn aggregate mediated inhibition of a single protein that regulates PI(3,5)P2 levels, or 
a downstream effector of this signaling lipid, could cause the phenotype we observed in 
α-syn aggregate bearing cells. Furthermore, the α-syn aggregates appear to be completely 
resistant to autophagy, whereas other autophagy substrates can still be degraded at slower 
rates. Therefore, it is not clear if a single defect is responsible of the failure of autophagy 
in degrading α-syn aggregates and the general impairment in autophagy. One could 
speculate that physical sequestration of the autophagosomes, or formation of 
defective/incomplete autophagosomes may be responsible for the former impairment, 
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whereas defects in vesicle trafficking contributes to the latter. Further studies are needed 
to investigate these pathways to elucidate the molecular mechanism of autophagosome 
impairment caused by α-syn aggregates.  
5.2 LB-like seeded aggregates and non-fibrillar α-syn inclusions 
The non-fibrillar smaller inclusions that are seen in several in vivo α-syn 
overexpression models may also form in human brain, particularly in regions where α-
syn is concentrated, such as synapses (Kramer & Schulz-Schaeffer, 2007). However, 
being susceptible to degradation these structures may not be readily detected. LBs and 
LNs may be a completely distinct group of aggregates, initiated by cell-to-cell 
transmission of α-syn seeds, and being resistant to degradation, these aggregates 
constitute the prominent lesions in synucleinopathies. It is postulated that α-syn 
aggregates are neuroprotective, or inert, and can be easily degraded by autophagy. 
However, these claims are mostly based on the data obtained from studies on non-fibrillar 
α-syn inclusions. Unlike many others, our α-syn aggregation models recapitulate LB-like 
α-syn aggregate formation, without forcing formation of other forms of α-syn 
accumulations. A major difference between these two types of α-syn accumulations is the 
former are usually generated as a result of “aggresomes response” through which 
misfolded proteins are actively sequestered and packaged by the cells to facilitate their 
degradation by autophagy (Kopito, 2000). In addition, they are likely to include many 
other proteins accumulated during the efforts to make α-syn accumulate, thus it is not 
clear if these inclusions are indeed α-syn inclusions or inclusions that merely contain α-
syn. On the other hand, it is likely that seeded α-syn aggregates do not rely on 
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“aggresomes response” to form in the cells, since it is clearly shown that purified 
recombinant α-syn can form aggregates that are ultrastructurally and biochemically very 
similar to LBs (Conway et al, 1998). Moreover, seeding with α-syn confers selectivity, 
and it did not cause accumulation of other aggregate prone proteins such as TDP-43 (data 
not shown), therefore seeded aggregates should basically be aggregates of α-syn 
including other proteins, not aggregates of other proteins including α-syn. This could 
explain why they are more similar to LBs, than aggresomes-like α-syn inclusions. 
Therefore, we believe our study provide a unique insight into possible impact of LBs on 
cellular pathways, and their susceptibility to removal by autophagy.  
5.3. Insights into the therapeutic implications of our study 
We believe that activation of autophagy can be a promising potential preventative 
therapy for synucleinopathies. It may reduce levels of monomeric α-syn, soluble 
oligomers and other types of α-syn accumulations, and possibly help delay LB formation 
by reducing available α-syn to be recruited. However, we also believe that activation of 
autophagy may not be a favorable approach after accumulation of LB and LN-like 
aggregates, which typically occurs before clinical symptoms manifest. At that point, 
autophagosome clearance may be impaired, and as previously discussed; activation of 
this pathway may exacerbate neurodegeneration under these conditions. Indeed, this 
result was not only observed by us in our cell based models, but also in an in vivo model 
of SOD-1 aggregation. SOD-1 mutations are implicated in amyotrophic lateral sclerosis 
(ALS), a lethal motor neurodegenerative disease (Deng et al, 1993), and in a mouse 
model of SOD-1 aggregation, it was observed that autophagosome clearance is reduced 
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(as indicated by accumulation of LC3-II and p62), and treatment of these mice with 
autophagy activator rapamycin does not help remove aggregates, but also exacerbates 
mitochondrial impairment, and augment neurodegeneration (Zhang et al, 2011).  
Our findings indicate that once they are formed, LB-like α-syn inclusions are 
refractory to removal; however, this does not indicate that their detrimental effects on the 
cells cannot be stopped. Elimination of the autophagy impairing effects of the aggregates 
may render the aggregates relatively inert, and despite their continued existence in the 
cells, they would have reduced cytotoxicity. For example, if recruitment of 
autophagosomes to the aggregates is stopped, perhaps by elimination of p62, autophagy 
function may not be affected by the aggregates. Alternatively, treatments that reduce 
autophagic activity may be beneficial if the cells have overactive autophagy that could be 
caused by a number of reasons such as age related impairment of other Pdps, and PD-
linked LRRK2 mutations (Bravo-San Pedro et al, 2012). In addition, treatments that 
would improve vesicular trafficking, such as expression of rab proteins, or restoration of 
PI(3,5)P2 levels could be beneficial if these factors are affected by α-syn aggregates. 
Therefore, it is very important to elucidate the underlying mechanism of autophagy 
impairment caused by LB-like α-syn aggregates.  
5.4 Insights into the possible interplay between LBs, autophagy and 
mitochondrial function in neurodegeneration  
Recent studies suggest that role of autophagy in PD pathogenesis may be more 
important than initially thought. Although the evidence indicating that mitochondrial 
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dysfunction has a primary role in PD pathogenesis is unequivocal, autophagy may be 
another primary player. Inhibition of autophagy in mouse neurons can cause 
neurodegeneration (Hara et al, 2006; Komatsu et al, 2006). For example, mice lacking 
atg5, a gene essential for autophagosome nucleation (Mizushima et al, 2001), in brain 
tissue, accumulates insoluble, ubiquitinated protein aggregates, followed by neuron loss 
through mechanisms including apoptosis (Hara et al, 2006). Moreover, autophagy 
deficient mice also show accumulation of deformed mitochondria and peroxisomes in 
liver, supporting the in vitro evidence that autophagy is crucial in clearing damaged 
organelles which could otherwise have cytotoxic effects (Komatsu et al, 2005). Finally, 
neurodegeneration is a common symptom of lysosomal storage disorders, which are 
caused by lysosomal defects affecting all members of the ALP pathway, including 
autophagy (Settembre et al, 2008). These findings support that similar to mitochondrial 
dysfunction, impaired autophagy may also cause neurodegeneration.  
If impaired autophagy and mitochondrial dysfunction are the major mechanism of 
neurodegeneration in PD and related synucleinopathies, risk factors for PD should have a 
direct or indirect effect on these toxic defects. Indeed, age, a major risk factor for PD, 
impairs mitochondria (Conley et al, 2007). Aging may also stress and activate autophagy 
by causing a decline in other Pdps, thereby increasing the dependence on autophagy to 
remove unwanted proteins (Farout & Friguet, 2006; Kiffin et al, 2007; Ma et al, 2011). 
Moreover, all genes whose mutations are linked to PD have roles in at least one of these 
pathways (Figure 5-2). ATP13A2 is important for lysosomal function (Usenovic et al, 
2012). Mutations in the lysosomal protein GBA can increase the risk of PD, and 
recessively inherited loss of function this protein causes a lysosomal strorage disease 
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(Gaucher‟s disease), indicating that this protein is important for ALP function (Nichols et 
al, 2009). Pink-1 and Parkin are not only involved in mitochondrial function but also 
crucial in autophagy mediated removal of defective mitochondria (mitophagy) (Narendra 
et al, 2008; Vives-Bauza et al, 2010). As well as the mitochondrial toxins commonly used 
to mimic parkinsonism (Gorell et al, 1998; Langston et al, 1999; Liou et al, 1997), DJ-1 
loss of function mutations also impair mitochondria (Guzman et al, 2010; Hao et al, 
2010). Finally, as we show here, the pathological hallmarks of PD, LBs, impair 
autophagy, which may cause cell death directly, or indirectly by causing accumulation of 
defective mitochondria. Interestingly, the most frequent LRRK2 mutation G2019S, which 
is observed in almost 40% of familial PD cases in certain populations, shown to activate 
autophagy (Bravo-San Pedro et al, 2012), and deletion of this gene, whose mutations are 
the most common cause of familial PD, reduces autophagic activity in aged mice (Tong 
et al, 2010) and also slows down pathogenesis in a A53T α-syn aggregation model (Lin et 
al, 2009). Thus, although many of these proteins, as well as α-syn, have also been 
implicated with processes unrelated to autophagy or mitochondrial function, with recent 
studies (some reviewed in(Lachenmayer & Yue, 2012), including ours, the evidence 
converged on these two pathways. Thus, impaired macroautophagy may be a primary 
cause of the neurodegeneration in PD and related synucleinopathies (Figure 5-1).  
What we did not discuss thus far is why a subset of neurons in PD, including 
dopaminergic neurons of SNc, and noradrenergic neurons of locus ceruleus, are much 
more vulnerable to degeneration than the other CNS neurons. This topic is still debated; 
one of the earliest theories was that the presence of dopamine in dopaminergic cells 
renders these cells vulnerable. For one, a number of studies provided evidence suggesting 
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that α-syn plays a role in the regulation of dopamine by modulating its production (Perez 
et al, 2002; Wu et al, 2011) and release (Larsen et al, 2006; Senior et al, 2008; Yavich et 
al, 2004), such that pathological changes in α-syn function may disrupt dopamine 
homeostasis. Moreover, oxidized dopamine derivatives can be toxic, rendering 
dopaminergic cells sensitive to mitochondrial dysfunction/oxidative stress (Anderson et 
al, 2011). An oxidized dopamine derivative, dopaminochrome, is also shown to interact 
with α-syn, and stabilize potentially toxic oligomeric species while inhibiting 
fibrillization (Norris et al, 2005). Additionally, it was suggested that α-syn forms soluble 
protein complexes that are normally neuroprotective, but these complexes increase the 
rate of apoptosis in the presence of dopamine (Xu et al, 2002). However, dopamine is not 
likely the only factor causing selective degeneration in PD. Firstly, many neurons which 
are lost in this disease, some before SNc neurons, such as noradrenergic locus ceruleus, 
histaminergic tuberomammillary nucleus (Del Tredici & Braak, 2004; German et al, 
1992; Surmeier et al, 2011) do not have dopamine. Second, in mice, unless α-syn 
expression is specifically targeted to dopaminergic neurons, SNc is often spared while α-
syn aggregation and neuron loss can be observed in many brain regions (Hashimoto et al, 
2003), suggesting that presence of dopamine may even be protective against α-syn 
pathology by inhibiting aggregation. Lastly, dopamine replacement therapies, such as 
administration of dopamine precursor L-dopa, do not promote disease progression (Fahn, 
2005). Arguably a better supported theory attempting to explain the selective 
vulnerability in PD, relies on the observation that the vulnerable neurons have 
autonomous pacemaking activity and are decorated with L-type Ca+2 channels, enabling 
Ca+2 influx coupled with this activity (Surmeier et al, 2011). Intracellular Ca+2 levels  
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Figure 0-1: A hypothetical model of neurodegeneration in PD   
 
 
 
Figure 5-1: A hypothetical model of neurodegeneration in PD This model is based 
on the hypothesis that impairments in autophagy and mitochondrial function are two 
major contributors of cell death observed in PD. Once formed, LBs may impair 
autophagosome clearance and this impairment can cause cell death directly by 
accumulation of misfolded and damaged proteins, and indirectly by impairing 
mitophagy resulting in increased numbers of damaged mitochondria that generate free 
radicals. This defect can result in oxidative stress, and elevation of intracellular Ca
+2
 
levels in dopaminergic cells, which both activates autophagy, further damaging the 
LB bearing cells that are unable to efficiently clear autophagosomes. Factors that can 
directly affect mitochondrial function (such as mitochondrial toxins, mutations in DJ-
1, Parkin and Pink-1, and possibly α-syn oligomers), mitophagy (mutations in Parkin 
and Pink-1), autophagy (mutations in ATP13A2, GBA), may also cause cell death 
independent of LBs. Mutations in LRRK2 may contribute to LB formation, as well as 
LB mediated cell death by activating autophagy. For simplicity, only select 
interactions are shown. It is likely that the actual interplay between these mutations 
and pathways is more complicated, considering that decades of relentless research on 
PD provided only modest progress in our understanding of the disease.  
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are to be kept exceedingly low at all times (100nM vs 10mM in extracellular space), 
since it is used as an signaling molecule and can form Ca3(PO4)2 precipitates at high 
concentrations. Restoration of low Ca
+2
 levels after Ca
+2
 influxes requires vast amounts 
of energy, which could put significant stress on mitochondria (Guzman et al, 2010; 
Wilson & Callaway, 2000). Moreover, along with oxidative stress , elevated intracellular 
Ca
+2
 also activates autophagy (Harr & Distelhorst, 2010), which might further increase 
the vulnerability of the neurons to LB-mediated autophagosome clearance impairment. 
Thus, it is possible that with their stressed mitochondria, and increased abundance of 
oxidatively damaged α-syn, vulnerable neurons are more prone to form de novo α-syn 
fibrils or seeded LBs. Moreover, once formed, impairment of autophagosome clearance 
by LBs would be particularly destructive to these vulnerable neurons, because of their 
activated autophagy, and their dependence on robust mitophagy to maintain a healthy 
pool of mitochondria. Impaired mitophagy may cause reduction in energy reserves, and 
inefficient Ca
+2
 removal, that would further activate autophagy, resulting in a vicious 
cycle consequently leading to cell death. 
5.5 Concluding remarks  
In this study, we investigated the interplay between LB-like α-syn aggregates and 
autophagy, and based on our findings, we believe that these aggregates significantly 
contribute to neurodegeneration by impairing autophagic clearance. We hope that our 
work constituted a primer for future studies that will further investigate the underlying 
mechanisms of this effect, thereby helping provide new therapeutic targets for these 
devastating diseases.  
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